-
Subject Areas on Research
-
1,10-Phenanthroline reversibility inhibits proliferation of two human prostate carcinoma cell lines (PC-3 and DU145).
-
111-In-capromab pendetide imaging using hybrid-γ camera-computer tomography technology is not reliable in detecting seminal vesicle invasion in patients with prostate cancer.
-
27-Hydroxycholesterol Impairs Plasma Membrane Lipid Raft Signaling as Evidenced by Inhibition of IL6-JAK-STAT3 Signaling in Prostate Cancer Cells.
-
3-D computer visualization and interactive prostate biopsy simulation leads to an improved systematic technique for the detection of prostate cancer: clinical correlation.
-
5α-Reductase inhibition coupled with short off cycles increases survival in the LNCaP xenograft prostate tumor model on intermittent androgen deprivation therapy.
-
6-Methylene progesterone is cytotoxic to human cancer cell lines independent of its 5-alpha-reductase activity.
-
9-Nitrocamptothecin as second line chemotherapy for men with progressive, metastatic, hormone refractory prostate cancer: Results of the CALGB 99901.
-
A "rolling average" multiple adaptive planning method to compensate for target volume changes in image-guided radiotherapy of prostate cancer.
-
A 6-Mb high-resolution physical and transcription map encompassing the hereditary prostate cancer 1 (HPC1) region.
-
A 66-year-old man with prostate-specific antigen recurrence and lung mass after radical prostatectomy.
-
A Case of Fatal Clostridial Necrotizing Fasciitis After Radical Prostatectomy.
-
A Comparative Effectiveness Trial of Alternate Formats for Presenting Benefits and Harms Information for Low-Value Screening Services: A Randomized Clinical Trial.
-
A Cross-Cancer Genetic Association Analysis of the DNA Repair and DNA Damage Signaling Pathways for Lung, Ovary, Prostate, Breast, and Colorectal Cancer.
-
A Human Adult Stem Cell Signature Marks Aggressive Variants across Epithelial Cancers.
-
A Multi-Institutional Prospective Trial Confirms Noninvasive Blood Test Maintains Predictive Value in African American Men.
-
A Multireader Exploratory Evaluation of Individual Pulse Sequence Cancer Detection on Prostate Multiparametric Magnetic Resonance Imaging (MRI).
-
A Nomogram for Testosterone Recovery After Combined Androgen Deprivation and Radiation Therapy for Prostate Cancer.
-
A comparison of conventional 'forward planning' with inverse planning for 3D conformal radiotherapy of the prostate.
-
A comparison of coplanar four-field techniques for conformal radiotherapy of the prostate.
-
A comparison of radical retropubic with perineal prostatectomy for localized prostate cancer within the Uniformed Services Urology Research Group.
-
A comprehensive evaluation of CHEK2 germline mutations in men with prostate cancer.
-
A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis.
-
A critical analysis of the long-term impact of radical prostatectomy on cancer control and function outcomes.
-
A decision aid for teaching limitations of prostate cancer screening.
-
A descriptive analysis of postimplant dosimetric parameters from Radiation Therapy Oncology Group P0019.
-
A dose-volume-based tool for evaluating and ranking IMRT treatment plans.
-
A framework to evaluate the cost-effectiveness of the NADiA ProsVue slope to guide adjuvant radiotherapy among men with high-risk characteristics following prostatectomy for prostate cancer.
-
A greedy heuristic using adjoint functions for the optimization of seed and needle configurations in prostate seed implant.
-
A high ratio of dietary n-6/n-3 polyunsaturated fatty acids is associated with increased risk of prostate cancer.
-
A human novel gene DERPC on 16q22.1 inhibits prostate tumor cell growth and its expression is decreased in prostate and renal tumors.
-
A hybrid strategy of offline adaptive planning and online image guidance for prostate cancer radiotherapy.
-
A knowledge-based approach to improving and homogenizing intensity modulated radiation therapy planning quality among treatment centers: an example application to prostate cancer planning.
-
A lifestyle intervention of weight loss via a low-carbohydrate diet plus walking to reduce metabolic disturbances caused by androgen deprivation therapy among prostate cancer patients: carbohydrate and prostate study 1 (CAPS1) randomized controlled trial.
-
A longitudinal assessment of bowel related symptoms and fecal incontinence following radical perineal prostatectomy.
-
A metalloporphyrin antioxidant alters cytokine responses after irradiation in a prostate tumor model.
-
A model for optimizing adenoviral delivery in human cancer gene therapy trials.
-
A multistate model for the genetic analysis of the ageing process.
-
A novel androgen-regulated gene, PMEPA1, located on chromosome 20q13 exhibits high level expression in prostate.
-
A novel antisense inhibitor of MMP-9 attenuates angiogenesis, human prostate cancer cell invasion and tumorigenicity.
-
A novel conditionally replicative adenovirus vector targeting telomerase-positive tumor cells.
-
A novel human cancer culture model for the study of prostate cancer.
-
A novel isoform ratio switch of the polypyrimidine tract binding protein.
-
A novel neoplastic primary tumor-derived human prostate epithelial cell line.
-
A paclitaxel-loaded recombinant polypeptide nanoparticle outperforms Abraxane in multiple murine cancer models.
-
A peripheral circulating TH1 cytokine profile is inversely associated with prostate cancer risk in CLUE II.
-
A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer.
-
A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy.
-
A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer.
-
A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006.
-
A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer.
-
A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer.
-
A phase II Hoosier Oncology Group study of vinorelbine and estramustine phosphate in hormone-refractory prostate cancer.
-
A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC).
-
A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: preliminary results of cancer and leukemia group B Trial 9780.
-
A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813.
-
A phase II study of estramustine, docetaxel, and exisulind in patients with hormone- refractory prostate cancer: results of cancer and leukemia group B trial 90004.
-
A phase II study of external beam radiotherapy combined with permanent source brachytherapy for intermediate-risk, clinically localized adenocarcinoma of the prostate: preliminary results of RTOG P-0019.
-
A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer.
-
A phase II study of weekly paclitaxel/estramustine/carboplatin in hormone-refractory prostate cancer.
-
A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer.
-
A planning quality evaluation tool for prostate adaptive IMRT based on machine learning.
-
A preliminary analysis of health-related quality of life in the first year after permanent source interstitial brachytherapy (PIB) for clinically localized prostate cancer.
-
A pretreatment nomogram for prediction of biochemical failure after primary cryoablation of the prostate.
-
A prognostic score for hormone-refractory prostate cancer: analysis of two cancer and leukemia group B studies.
-
A prospective analysis of patient-reported quality of life after prostate brachytherapy.
-
A prospective quality-of-life study in men with clinically localized prostate carcinoma treated with radical prostatectomy, external beam radiotherapy, or interstitial brachytherapy.
-
A prostate screening perspective.
-
A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma: cancer and leukemia group B study 9181.
-
A randomized trial of diet in men with early stage prostate cancer on active surveillance: rationale and design of the Men's Eating and Living (MEAL) Study (CALGB 70807 [Alliance]).
-
A retrospective comparison of anesthetic management of robot-assisted laparoscopic radical prostatectomy versus radical retropubic prostatectomy.
-
A role for the G12 family of heterotrimeric G proteins in prostate cancer invasion.
-
A serologic approach to the definition of human prostatic carcinoma antigens.
-
A simple model predicts freedom from biochemical recurrence after low-dose rate prostate brachytherapy alone.
-
A single-institution comparison between radical perineal and radical retropubic prostatectomy on perioperative and pathological outcomes for obese men: an analysis of the Duke Prostate Center database.
-
A small molecule inhibitor of isoprenylcysteine carboxymethyltransferase induces autophagic cell death in PC3 prostate cancer cells.
-
A structural approach to examining prostate cancer risk for rural southern African American men.
-
A structured literature review to determine the use of the American Society for Therapeutic Radiology and Oncology consensus definition of biochemical failure.
-
A systematic review of hypofractionation for primary management of prostate cancer.
-
A telomerase-immortalized primary human prostate cancer clonal cell line with neoplastic phenotypes.
-
A three-dimensional deformable model for segmentation of human prostate from ultrasound images.
-
A time-dependent statistical model which relates current clinical status to prognosis: application to advanced prostatic cancer.
-
A transgenic mouse prostate cancer model.
-
A year of successful cancer vaccines points to a path forward.
-
ACR Appropriateness Criteria® Hematospermia.
-
ACR Appropriateness Criteria® Post-treatment Follow-up Prostate Cancer.
-
ACR Appropriateness Criteria® Prostate Cancer-Pretreatment Detection, Surveillance, and Staging.
-
ACR appropriateness criteria on external beam radiation therapy treatment planning for clinically localized prostate cancer expert panel on radiation oncology--prostate.
-
ADAM metallopeptidase domain 17 (ADAM17) is naturally processed through major histocompatibility complex (MHC) class I molecules and is a potential immunotherapeutic target in breast, ovarian and prostate cancers.
-
ADT risks and side effects in advanced prostate cancer: cardiovascular and acute renal injury.
-
ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer.
-
Abdominal and pelvic adipose tissue distribution and risk of prostate cancer recurrence after radiation therapy.
-
Aberrant activation of hepatocyte growth factor/MET signaling promotes β-catenin-mediated prostatic tumorigenesis.
-
Abi1 loss drives prostate tumorigenesis through activation of EMT and non-canonical WNT signaling.
-
Ability of C-reactive protein to complement multiple prognostic classifiers in men with metastatic castration resistant prostate cancer receiving docetaxel-based chemotherapy.
-
Abiraterone in metastatic prostate cancer without previous chemotherapy.
-
Absence of a correlation of androgen receptor gene CAG repeat length and prostate cancer risk in an African-American population.
-
Accessory parotid glands as a site of metastases from outside the head and neck: case report.
-
Accuracy of predicting long-term prostate specific antigen outcome based on early prostate specific antigen recurrence results after radical prostatectomy.
-
Achieving treatment goals for hormone-refractory prostate cancer with chemotherapy.
-
Acoustic radiation force impulse imaging of human prostates ex vivo.
-
Activated α2-macroglobulin binding to human prostate cancer cells triggers insulin-like responses.
-
Activation and cross-talk between Akt, NF-kappaB, and unfolded protein response signaling in 1-LN prostate cancer cells consequent to ligation of cell surface-associated GRP78.
-
Activation of Rap1 promotes prostate cancer metastasis.
-
Activation of the PKB/Akt pathway in histological benign prostatic tissue adjacent to the primary malignant lesions.
-
Active surveillance as a treatment option for prostate cancer.
-
Active surveillance for African-American men with prostate cancer: of course! Pro.
-
Active surveillance for early-stage prostate cancer: review of the current literature.
-
Active surveillance for prostate cancer: can we modernize contemporary protocols to improve patient selection and outcomes in the focal therapy era?
-
Activities and accomplishments of the cancer and leukemia group B genitourinary committee.
-
Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors.
-
Activity of psoralen-functionalized nanoscintillators against cancer cells upon X-ray excitation.
-
Activity of the herbal combination, PC-SPES, in the treatment of patients with androgen-independent prostate cancer.
-
Acute Presentation of Previously Unrecognized Congenital Ureteropelvic Junction Obstruction 5 Weeks After Radical Retropubic Prostatectomy.
-
Acute urinary retention associated with prostatic carcinoma.
-
Acute urinary toxicity following transperineal prostate brachytherapy using a modified Quimby loading method.
-
Adaptive prostate IGRT combining online re-optimization and re-positioning: a feasibility study.
-
Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data.
-
Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics.
-
Adenocarcinoma of the prostate. I. Tissue sampling considerations.
-
Adenocarcinoma of the prostate. Part II: Tissue prognosticators.
-
Adenocarcinoma of the prostate: an expensive way to die.
-
Adenocarcinoma of the prostate: epidemiological trends, screening, diagnosis, and surgical management of localized disease.
-
Adenocarcinoma of the prostate: stage A1.
-
Adiponectin and prostate cancer mortality: to be or not to be skinny?
-
Adjuvant and salvage radiation therapy after prostatectomy: American Society for Radiation Oncology/American Urological Association guidelines.
-
Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO Guideline.
-
Adjuvant radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate: ten-year update.
-
Adjuvant versus salvage radiation therapy for prostate cancer and the risk of death.
-
Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B study.
-
Adrenocortical hyperplasia occurring with metastatic carcinoma of the prostate: report of a case exhibiting increased urinary aldosterone and glucocorticoid excretion.
-
Adult Patients' Perspectives on the Benefits and Harms of Overused Screening Tests: a Qualitative Study.
-
Adult cancer survivors discuss follow-up in primary care: 'not what i want, but maybe what i need'.
-
Advanced imaging and hospice use in end-of-life cancer care.
-
Advanced prostate cancer: the future.
-
Advanced prostatic carcinoma: pulmonary manifestations.
-
Advanced topics in evidence-based urological oncology: using results of a subgroup analysis.
-
Adverse pathology and undetectable ultrasensitive prostate-specific antigen after radical prostatectomy: is adjuvant radiation warranted?
-
African American Men With Low-Risk Prostate Cancer Are Candidates for Active Surveillance: The Will-Rogers Effect?
-
African-American heredity prostate cancer study: a model for genetic research.
-
African-American heredity prostate cancer study: a model for genetic research.
-
After radical retropubic prostatectomy 'insignificant' prostate cancer has a risk of progression similar to low-risk 'significant' cancer.
-
Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening.
-
Age-specific reference ranges for serum prostate-specific antigen in black men.
-
Aging and neoplasia.
-
Agreement between a brief mailed screener and an in-depth telephone survey: observations from the Fresh Start study.
-
Alcohol intake increases high-grade prostate cancer risk among men taking dutasteride in the REDUCE trial.
-
Algorithm and performance of a clinical IMRT beam-angle optimization system.
-
Allelic loss on chromosome 6Q in primary prostate cancer.
-
Alteration of the tumor suppressor gene p53 in a high fraction of hormone refractory prostate cancer.
-
Alterations of the P53 gene are associated with the progression of a human prostate carcinoma.
-
Altered male physiologic function after surgery for prostate cancer: couple perspective.
-
Alternative Splicing Provides a Novel Molecular Mechanism for Prostatic Small-cell Neuroendocrine Carcinoma.
-
Alternative inclusion of fibroblast growth factor receptor 2 exon IIIc in Dunning prostate tumors reveals unexpected epithelial mesenchymal plasticity.
-
Alternative splicing of fibroblast growth factor receptor 2 (FGF-R2) in human prostate cancer.
-
Alternative splicing promotes tumour aggressiveness and drug resistance in African American prostate cancer.
-
American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy.
-
American Society for Radiation Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the transperineal permanent brachytherapy of prostate cancer.
-
An In Vivo Screen Identifies PYGO2 as a Driver for Metastatic Prostate Cancer.
-
An Internet intervention for management of uncertainty during active surveillance for prostate cancer.
-
An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer.
-
An atypical case of fatal zygomycosis: simultaneous cutaneous and laryngeal infection in a patient with a non-neutropenic solid prostatic tumor.
-
An automatic CT-guided adaptive radiation therapy technique by online modification of multileaf collimator leaf positions for prostate cancer.
-
An examination of the dynamic changes in prostate-specific antigen occurring in a population-based cohort of men over time.
-
An intronic splicing silencer causes skipping of the IIIb exon of fibroblast growth factor receptor 2 through involvement of polypyrimidine tract binding protein.
-
An item response theory-based pain item bank can enhance measurement precision.
-
An update of research evidence on nutrition and prostate cancer.
-
Analysis of laterality and percentage of tumor involvement in 1386 prostatectomized specimens for selection of unilateral focal cryotherapy.
-
Analysis of urinary function using validated instruments and uroflowmetry after primary and salvage prostate cryoablation.
-
Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens.
-
Androgen and androgen receptor antagonist responsive primary African-American benign prostate epithelial cell line.
-
Androgen deprivation therapy for prostate cancer results in significant loss of bone density.
-
Androgen receptor activation by G(s) signaling in prostate cancer cells.
-
Androgen receptor down-regulation in prostate cancer with phosphorodiamidate morpholino antisense oligomers.
-
Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663.
-
Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting.
-
Androgen receptor with short polyglutamine tract preferably enhances Wnt/β-catenin-mediated prostatic tumorigenesis.
-
Androgen-deprivation therapy and metabolic syndrome in men with prostate cancer.
-
Androgen-independent prostate cancer progression in the TRAMP model.
-
Androgen-induced expression of endoplasmic reticulum (ER) stress response genes in prostate cancer cells.
-
Androgens promote prostate cancer cell growth through induction of autophagy.
-
Androgens regulate prostate cancer cell growth via an AMPK-PGC-1α-mediated metabolic switch.
-
Aneuploidy of chromosome 9 and the tumor suppressor genes p16(INK4) and p15(INK4B) detected by in situ hybridization in locally advanced prostate cancer.
-
Angiogenesis, p53, bcl-2 and Ki-67 in the progression of prostate cancer after radical prostatectomy.
-
Angiostatin directly inhibits human prostate tumor cell invasion by blocking plasminogen binding to its cellular receptor, CD26.
-
Angiotensin receptor signaling and prostate tumor growth in mice.
-
Angiotropism of human prostate cancer cells: implications for extravascular migratory metastasis.
-
Anterior gland focal cryoablation: proof-of-concept primary prostate cancer treatment in select men with localized anterior cancers detected by multi-parametric magnetic resonance imaging.
-
Anterior rectal wall gastrointestinal stromal tumor presenting clinically as prostatic mass.
-
Anthropometric risk factors for prostate cancer.
-
Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).
-
Antigenic activity of human urothelial tissue.
-
Antiproliferative effects of cyclocreatine on human prostatic carcinoma cells.
-
Anxiety symptoms prior to a prostate cancer diagnosis: Associations with knowledge and openness to treatment.
-
Apical soft tissue biopsies predict biochemical failure in radical perineal prostatectomy patients with apical cancer involvement.
-
Apical surgical margins status in robot-assisted laparoscopic radical prostatectomy does not depend on disease characteristics.
-
Apparent Diffusion Coefficient Values of the Benign Central Zone of the Prostate: Comparison With Low- and High-Grade Prostate Cancer.
-
Application of dose compensation in image-guided radiotherapy of prostate cancer.
-
Application of oligonucleotide microarrays to assess the biological effects of neoadjuvant imatinib mesylate treatment for localized prostate cancer.
-
Arc-modulated radiation therapy based on linear models.
-
Are COVID-19 Delays a Basis for Concern? Can We Use This for Future Good?
-
Are Small Reimbursement Changes Enough to Change Cancer Care? Reimbursement Variation in Prostate Cancer Treatment.
-
Are we overtreating prostate cancer?
-
Aspiration biopsy of prostate.
-
Aspirin, NSAIDs, and risk of prostate cancer: results from the REDUCE study.
-
Assessing adverse events of postprostatectomy radiation therapy for prostate cancer: evaluation of outcomes in the Regione Emilia-Romagna, Italy.
-
Assessing clinically significant prostate cancer: Diagnostic properties of multiparametric magnetic resonance imaging compared to three-dimensional transperineal template mapping histopathology.
-
Assessing the Prognostic Value of the Automated Bone Scan Index for Prostate Cancer-Reply.
-
Assessment of anatomic extent and biologic hazard of prostatic adenocarcinoma.
-
Assessment of circulating tumor cells (CTCs) in prostate cancer patients with low-volume tumors.
-
Association Between Choice of Radical Prostatectomy, External Beam Radiotherapy, Brachytherapy, or Active Surveillance and Patient-Reported Quality of Life Among Men With Localized Prostate Cancer.
-
Association Between Early Confirmatory Testing and the Adoption of Active Surveillance for Men With Favorable-risk Prostate Cancer.
-
Association between Adult Height and Risk of Colorectal, Lung, and Prostate Cancer: Results from Meta-analyses of Prospective Studies and Mendelian Randomization Analyses.
-
Association between percentage of tumor involvement and Gleason score upgrading in low-risk prostate cancer.
-
Association between preoperative erectile dysfunction and prostate cancer features--an analysis from the Duke Prostate Center Database.
-
Association between statins and prostate tumor inflammatory infiltrate in men undergoing radical prostatectomy.
-
Association of Black Race With Prostate Cancer-Specific and Other-Cause Mortality.
-
Association of LEP G2548A and LEPR Q223R polymorphisms with cancer susceptibility: evidence from a meta-analysis.
-
Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer.
-
Association of plasminogen with dipeptidyl peptidase IV and Na+/H+ exchanger isoform NHE3 regulates invasion of human 1-LN prostate tumor cells.
-
Association of rash with outcomes in a randomized phase II trial evaluating cetuximab in combination with mitoxantrone plus prednisone after docetaxel for metastatic castration-resistant prostate cancer.
-
Association of uridine diphosphate-glucuronosyltransferase 2B gene variants with serum glucuronide levels and prostate cancer risk.
-
Associations Between Prostate Volume and Oncologic Outcomes in Men Undergoing Focal Cryoablation of the Prostate.
-
Associations between RNA splicing regulatory variants of stemness-related genes and racial disparities in susceptibility to prostate cancer.
-
Associations between lifestyle factors and quality of life among older long-term breast, prostate, and colorectal cancer survivors.
-
Associations of prostate cancer risk variants with disease aggressiveness: results of the NCI-SPORE Genetics Working Group analysis of 18,343 cases.
-
Atlas-guided prostate intensity modulated radiation therapy (IMRT) planning.
-
Autoantibodies against the cell surface-associated chaperone GRP78 stimulate tumor growth via tissue factor.
-
Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors.
-
Automatic IMRT planning via static field fluence prediction (AIP-SFFP): a deep learning algorithm for real-time prostate treatment planning.
-
Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemonaïve castration-resistant prostate cancer.
-
B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy.
-
BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers.
-
Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults.
-
Balancing Risks in Prostate-specific Antigen Recurrence: The Fox Versus the Hedgehog.
-
Baseline PSA as a predictor of prostate cancer-specific mortality over the past 2 decades: Duke University experience.
-
Baseline Prostate Atrophy is Associated with Reduced Risk of Prostate Cancer in Men Undergoing Repeat Prostate Biopsy.
-
Baseline prostate-specific antigen testing at a young age.
-
Baseline subject characteristics predictive of compliance with study-mandated prostate biopsy in men at risk of prostate cancer: results from REDUCE.
-
Bcl-2 accelerates multistep prostate carcinogenesis in vivo.
-
Beam orientation selection for intensity-modulated radiation therapy based on target equivalent uniform dose maximization.
-
Beam-orientation customization using an artificial neural network.
-
Best screening tests for prostate cancer.
-
Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance).
-
Bilateral paraneoplastic optic neuropathy and unilateral retinal compromise in association with prostate cancer: a differential diagnostic challenge in a patient with unexplained visual loss.
-
Binding of anti-GRP78 autoantibodies to cell surface GRP78 increases tissue factor procoagulant activity via the release of calcium from endoplasmic reticulum stores.
-
Biochemical recurrence after definitive prostate cancer therapy. Part I: defining and localizing biochemical recurrence of prostate cancer.
-
Biochemical recurrence after definitive prostate cancer therapy. Part II: treatment strategies for biochemical recurrence of prostate cancer.
-
Biochemical recurrence of prostate cancer.
-
Biologically effective dose (BED) correlation with biochemical control after low-dose rate prostate brachytherapy for clinically low-risk prostate cancer.
-
Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer.
-
Biopsy Detected Gleason Pattern 5 is Associated with Recurrence, Metastasis and Mortality in a Cohort of Men with High Risk Prostate Cancer.
-
Biopsy accuracy in identifying unilateral prostate cancer depends on prostate weight.
-
Biostatistical modeling using traditional preoperative and pathological prognostic variables in the selection of men at high risk for disease recurrence after radical prostatectomy for prostate cancer.
-
Biostatistical modeling using traditional variables and genetic biomarkers for predicting the risk of prostate carcinoma recurrence after radical prostatectomy.
-
Black race is an adverse prognostic factor for prostate cancer recurrence following radical prostatectomy in an equal access health care setting.
-
Bladder cancer.
-
Bladder cancer. Clinical guidelines in oncology.
-
Blinded evaluation of reverse transcriptase-polymerase chain reaction prostate-specific antigen peripheral blood assay for molecular staging of prostate cancer.
-
Blood and dietary magnesium levels are not linked with lower prostate cancer risk in black or white men.
-
Body composition and serum prostate-specific antigen: review and findings from Flint Men's Health Study.
-
Body dimension differences in men with or without prostate cancer.
-
Body mass index and prostate specific antigen as predictors of adverse pathology and biochemical recurrence after prostatectomy.
-
Body mass index, prostate-specific antigen, and digital rectal examination findings among participants in a prostate cancer screening clinic.
-
Bone health in prostate cancer patients receiving androgen-deprivation therapy: the role of bisphosphonates.
-
Bone marrow biopsy: RNA isolation with expression profiling in men with metastatic castration-resistant prostate cancer--factors affecting diagnostic success.
-
Brachytherapy using injectable seeds that are self-assembled from genetically encoded polypeptides in situ.
-
Bradykinin receptor subtype 1 expression and function in prostate cancer.
-
Bromodomain protein 4 discriminates tissue-specific super-enhancers containing disease-specific susceptibility loci in prostate and breast cancer.
-
Building a high-resolution T2-weighted MR-based probabilistic model of tumor occurrence in the prostate.
-
CCDC62/ERAP75 functions as a coactivator to enhance estrogen receptor beta-mediated transactivation and target gene expression in prostate cancer cells.
-
CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy.
-
COVID-19 impact on timing of brachytherapy treatment and strategies for risk mitigation.
-
CYP27A1 Loss Dysregulates Cholesterol Homeostasis in Prostate Cancer.
-
CaM kinase kinase beta-mediated activation of the growth regulatory kinase AMPK is required for androgen-dependent migration of prostate cancer cells.
-
CaMKK2: a novel target for shaping the androgen-regulated tumor ecosystem.
-
Cadmium-induced neoplastic transformation of human prostate epithelial cells.
-
Calcium/calmodulin-dependent protein kinase kinase 2: roles in signaling and pathophysiology.
-
Can Radiologic Staging With Multiparametric MRI Enhance the Accuracy of the Partin Tables in Predicting Organ-Confined Prostate Cancer?
-
Can electronic web-based technology improve quality of life data collection? Analysis of Radiation Therapy Oncology Group 0828.
-
Can prostate-specific antigen and prostate-specific antigen velocity be used for prostate cancer screening in men older than 70 years?
-
Can the conventional sextant prostate biopsy accurately predict unilateral prostate cancer in low-risk, localized, prostate cancer?
-
Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer.
-
Cancer control after low-dose-rate prostate brachytherapy performed by a multidisciplinary team with no previous prostate brachytherapy experience.
-
Cancer disparities in people with HIV: A systematic review of screening for non-AIDS-defining malignancies.
-
Cancer incidence among patients of the U.S. Veterans Affairs Health Care System.
-
Cancer survivors' health worries and associations with lifestyle practices.
-
Cancer-associated fibroblasts promote directional cancer cell migration by aligning fibronectin.
-
Cancer-specific concerns and physical activity among recently diagnosed breast and prostate cancer survivors.
-
Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era.
-
Capromab Pendetide imaging of prostate cancer.
-
Carbohydrate intake, glycemic index and prostate cancer risk.
-
Carbohydrate restriction and lactate transporter inhibition in a mouse xenograft model of human prostate cancer.
-
Carbohydrate restriction, prostate cancer growth, and the insulin-like growth factor axis.
-
Carcinoembryonic antigen as an adjunct to determination of clinical stage in prostate cancer.
-
Carcinogenesis in urogenital sites.
-
Carcinoma extent in prostate needle biopsy tissue in the prediction of whole gland tumor volume in a screening population.
-
Carcinoma of the prostate: the therapeutic dilemma.
-
Cathepsin D and epidermal growth factor receptor immunohistochemistry does not predict recurrence of prostate cancer in patients undergoing radical prostatectomy.
-
Cell cycle-independent death of prostate adenocarcinoma is induced by the trk tyrosine kinase inhibitor CEP-751 (KT6587).
-
Cell signaling modifiers in prostate cancer.
-
Cell surface adenosine deaminase binds and stimulates plasminogen activation on 1-LN human prostate cancer cells.
-
Cell surface glycoproteomic analysis of prostate cancer-derived PC-3 cells.
-
Cell-specific aptamers for targeted therapies.
-
Cellular and molecular mechanisms of pomegranate juice-induced anti-metastatic effect on prostate cancer cells.
-
Cellular migration and invasion uncoupled: increased migration is not an inexorable consequence of epithelial-to-mesenchymal transition.
-
Challenges in Reporting the Effect of Radiotherapy on Erectile Function.
-
Change in self-efficacy partially mediates the effects of the FRESH START intervention on cancer survivors' dietary outcomes.
-
Changes in Gleason score grading and their effect in predicting outcome after radical prostatectomy.
-
Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study.
-
Changes in bone health and skeletal-related events following implementation of a multidisciplinary consensus statement guiding surveillance and treatment of men undergoing androgen deprivation therapy for prostate cancer.
-
Changes in initial treatment for prostate cancer among Medicare beneficiaries, 1999-2007.
-
Changes in insurance coverage for cancer patients receiving brachytherapy before and after enactment of the Affordable Care Act.
-
Changing face and different countenances of prostate cancer: racial and geographic differences in prostate-specific antigen (PSA), stage, and grade trends in the PSA era.
-
Chaperones and disease.
-
Characteristics of baseline PSA and PSA velocity in young men without prostate cancer: Racial differences.
-
Characteristics of men reporting for prostate cancer screening.
-
Characterization and predictors of prostate specific antigen progression rates after radical retropubic prostatectomy.
-
Characterization of a "low-risk" cohort of grade group 2 prostate cancer patients: Results from the Shared Equal Access Regional Cancer Hospital database.
-
Characterization of a human prostate adenocarcinoma cell line (DU 145) as a monolayer culture and as a solid tumor in athymic mice.
-
Characterization of a new model of human prostatic cancer: the multicellular tumor spheroid.
-
Characterization of frequently deleted 6q locus in prostate cancer.
-
Characterization of prostate-tissue-directed monoclonal antibody, alpha-Pro 13.
-
Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model.
-
Characterizing stiffness of human prostates using acoustic radiation force.
-
Chemotherapy for advanced prostate cancer: results of new clinical trials and future studies.
-
Choosing wisely: the American Society for Radiation Oncology's top 5 list.
-
Chylothorax: a rare complication of metastatic prostatic carcinoma.
-
Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium.
-
Circulating Tumor Cell Phenotyping via High-Throughput Acoustic Separation.
-
Circulating Tumor Cells in Biochemical Recurrence of Prostate Cancer.
-
Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers.
-
Circulating vitamin D concentration and risk of seven cancers: Mendelian randomisation study.
-
Circulating vitamin D concentrations and risk of breast and prostate cancer: a Mendelian randomization study.
-
Clinical Application of Point-of-Care Ultrasound Gastric Examination in the Management of an ASA Class 3E Patient: A Case Report.
-
Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide.
-
Clinical and biochemical evidence of control of prostate cancer at 5 years after external beam radiation.
-
Clinical applications of dendritic cell vaccines.
-
Clinical characteristics of African-American men with hereditary prostate cancer: the AAHPC Study.
-
Clinical endpoints for drug development in prostate cancer.
-
Clinical evaluation of positioning verification using digital tomosynthesis and bony anatomy and soft tissues for prostate image-guided radiotherapy.
-
Clinical outcomes by age in men with hormone refractory prostate cancer: a pooled analysis of 8 Cancer and Leukemia Group B (CALGB) studies.
-
Clinical pharmacology of an atrasentan and docetaxel regimen in men with hormone-refractory prostate cancer.
-
Clinical roundtable monograph: new and emerging treatments for advanced prostate cancer.
-
Clinical staging of prostate cancer: reproducibility and clarification of issues.
-
Clinical utility of FoundationOne tissue molecular profiling in men with metastatic prostate cancer.
-
Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy.
-
Clinical variables which serve as predictors of cancer-specific survival among patients treated with radical cystectomy for transitional cell carcinoma of the bladder and prostate.
-
Clinically detected carcinoma of the prostate treated by radical prostatectomy in a 29-year-old man.
-
Clinically localized prostatic carcinoma.
-
Clinically relevant changes in family history of cancer over time.
-
Clinicopathological features to distinguish malignant solitary fibrous tumors of the prostate from prostatic stromal tumors.
-
Combination external beam radiation and brachytherapy boost with androgen deprivation for treatment of intermediate-risk prostate cancer: long-term results of CALGB 99809.
-
Combination external beam radiation and brachytherapy boost with androgen suppression for treatment of intermediate-risk prostate cancer: an initial report of CALGB 99809.
-
Combination hormonal therapy: a reassessment within advanced prostate cancer.
-
Combination of low-dose flutamide and finasteride for PSA-only recurrent prostate cancer after primary therapy.
-
Combined antegrade and retrograde endoscopic approach for the management of urinary diversion-associated pathology.
-
Combined external beam irradiation and external regional hyperthermia for locally advanced adenocarcinoma of the prostate.
-
Combined low-dose flutamide plus finasteride vs low-dose flutamide monotherapy for recurrent prostate cancer: a comparative analysis of two phase II trials with a long-term follow-up.
-
Combining prostate specific antigen with cancer and gland volume to predict more reliably pathological stage: the influence of prostate specific antigen cancer density.
-
Comments on: High-dose-rate interstitial brachytherapy as monotherapy in one fraction of 20.5 Gy for the treatment of localize prostate cancer: toxicity and 6-years biochemical results.
-
Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group.
-
Comparative effectiveness research in cancer genomics and precision medicine: current landscape and future prospects.
-
Comparative morphology of primary and secondary deposits of prostatic adenocarcinoma.
-
Comparing 3-T multiparametric MRI and the Partin tables to predict organ-confined prostate cancer after radical prostatectomy.
-
Comparing radical prostatectomy and brachytherapy for localized prostate cancer.
-
Comparison Between Adjuvant and Early-Salvage Postprostatectomy Radiotherapy for Prostate Cancer With Adverse Pathological Features.
-
Comparison of DRE and PSA in the Detection of Prostate Cancer.
-
Comparison of Outcomes Between Preoperatively Potent Men Treated with Focal Versus Whole Gland Cryotherapy in a Matched Population.
-
Comparison of Patient Report and Medical Records of Comorbidities: Results From a Population-Based Cohort of Patients With Prostate Cancer.
-
Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer.
-
Comparison of clinical staging algorithms and 111indium-capromab pendetide immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients.
-
Comparison of online IGRT techniques for prostate IMRT treatment: adaptive vs repositioning correction.
-
Comparison of prostate-specific antigen recurrence-free survival in a contemporary cohort of patients undergoing either radical retropubic or robot-assisted laparoscopic radical prostatectomy.
-
Comparison of radical prostatectomy and iodine 125 interstitial radiotherapy for the treatment of clinically localized prostate cancer: a 7-year biochemical (PSA) progression analysis.
-
Comparison of serum prostate specific membrane antigen, prostate specific antigen, and free prostate specific antigen levels in radical prostatectomy patients.
-
Comparison of similarity measures for rigid-body CT/Dual X-ray image registrations.
-
Comparison of treatment techniques for conformal radiotherapy of the prostate using dose-volume histograms and normal tissue complication probabilities.
-
Comparison of ultrasound-guided biopsies and prostatectomy specimens: predictive accuracy of Gleason score and tumor site.
-
Complete embedding and close step-sectioning of radical prostatectomy specimens both increase detection of extra-prostatic extension, and correlate with increased disease-free survival by stage of prostate cancer patients.
-
Complete high-intensity focused ultrasound in prostate cancer: outcome from the @-Registry.
-
Complications and postoperative events after cryosurgery for prostate cancer.
-
Comprehensive preoperative evaluation and repair of inguinal hernias at the time of open radical retropubic prostatectomy decreases risk of developing postprostatectomy hernia.
-
Computed high b-value diffusion-weighted imaging improves lesion contrast and conspicuity in prostate cancer.
-
Computed tomography-guided bilateral transdiscal superior hypogastric plexus neurolysis.
-
Computer-controlled delivery of 3D conformal radiation treatments.
-
Concordance in the perception of couples recovering from primary surgical treatment of prostate cancer.
-
Cone-beam-CT guided radiation therapy: A model for on-line application.
-
Cone-beam-CT guided radiation therapy: technical implementation.
-
Confirmatory Magnetic Resonance Imaging with or without Biopsy Impacts Decision Making in Newly Diagnosed Favorable Risk Prostate Cancer.
-
Conformal radiation treatment of prostate cancer using inversely-planned intensity-modulated photon beams produced with dynamic multileaf collimation.
-
Conformal technique dose escalation for prostate cancer: biochemical evidence of improved cancer control with higher doses in patients with pretreatment prostate-specific antigen > or = 10 NG/ML.
-
Conformal treatment of prostate cancer with improved targeting: superior prostate-specific antigen response compared to standard treatment.
-
Consensus Statement on Circulating Biomarkers for Advanced Prostate Cancer.
-
Considerations in fractionated proton radiation therapy: clinical potential and results.
-
Considerations of germline testing in prostate cancer screening.
-
Contemporary chemotherapeutic approaches for the treatment of hormone-refractory prostate carcinoma.
-
Contemporary hormonal management of advanced prostate cancer.
-
Contemporary results of focal therapy for prostate cancer using cryoablation.
-
Controversies in the treatment of prostate cancer with maximal androgen deprivation.
-
Convergence of oncogenic and hormone receptor pathways promotes metastatic phenotypes.
-
Coping with sexual concerns after cancer: the use of flexible coping.
-
Copper signaling axis as a target for prostate cancer therapeutics.
-
Correlation of DNA ploidy and histologic diagnosis from prostate core-needle biopsies: is DNA ploidy more sensitive than histology for the diagnosis of carcinoma in small specimens?
-
Correlation of prostate-specific antigen nadir and biochemical failure after high-intensity focused ultrasound of localized prostate cancer based on the Stuttgart failure criteria - analysis from the @-Registry.
-
Correspondence re: E. Hawk, et al., Male pattern baldness and clinical prostate cancer in the epidemiologic follow-up of the First National Health and Nutrition Examination Survey. Cancer Epidemiol.Biomark. Prev., 9: 523-527, 2000.
-
Cost comparison of radical retropubic and radical perineal prostatectomy: single institution experience.
-
Cost implications of PSA screening differ by age.
-
Cost-Effectiveness of Metastasis-Directed Therapy in Oligorecurrent Hormone-Sensitive Prostate Cancer.
-
Cost-Effectiveness of Primary Radiation Therapy Versus Radical Prostatectomy for Intermediate- to High-Risk Prostate Cancer.
-
Cost-effective models for flutamide for prostate carcinoma patients: are they helpful to policy makers?
-
Cost-effectiveness of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer.
-
Counterpoint: Which Treatment Modality for Localized Prostate Cancer Yields Superior Quality of Life: Radiotherapy or Prostatectomy? Most Men With Clinically Important Localized Prostate Cancer Deserve First-Line Open or Robotic Radical Prostatectomy.
-
County-level cumulative environmental quality associated with cancer incidence.
-
Creating value in health by understanding and overcoming resistance to de-innovation.
-
Critical review: is watchful waiting a viable management option for older men with prostate cancer?
-
Cross Cancer Genomic Investigation of Inflammation Pathway for Five Common Cancers: Lung, Ovary, Prostate, Breast, and Colorectal Cancer.
-
Cross-Cancer Genome-Wide Analysis of Lung, Ovary, Breast, Prostate, and Colorectal Cancer Reveals Novel Pleiotropic Associations.
-
Curcumin down-regulates AR gene expression and activation in prostate cancer cell lines.
-
Current health behaviors and readiness to pursue life-style changes among men and women diagnosed with early stage prostate and breast carcinomas.
-
Current issues in prostate cancer. Introduction.
-
Current salvage methods for recurrent prostate cancer after failure of primary radiotherapy.
-
Current trends and new frontiers in focal therapy for localized prostate cancer.
-
Cyclocreatine inhibits stimulated motility in tumor cells possessing creatine kinase.
-
Cytokine Gene Polymorphisms Associated With Symptom Clusters in Oncology Patients Undergoing Radiation Therapy.
-
DNA in radical prostatectomy specimens. Prognostic value of tumor ploidy.
-
DNA repair genes: contributions to prostate cancer predisposition and aggressiveness.
-
Daily bone alignment with limited repeat CT correction rivals daily ultrasound alignment for prostate radiotherapy.
-
Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study.
-
Data pooling and analysis to build a preliminary item bank: an example using bowel function in prostate cancer.
-
Defining low-value PSA testing in a large retrospective cohort: Finding common ground between discordant guidelines.
-
Defining potency: a comparison of the International Index of Erectile Function short version and the Expanded Prostate Cancer Index Composite.
-
Defining the Incremental Utility of Prostate Multiparametric Magnetic Resonance Imaging at Standard and Specialized Read in Predicting Extracapsular Extension of Prostate Cancer.
-
Definitive external beam irradiation in stage T1 and T2 carcinoma of the prostate. American College of Radiology. ACR Appropriateness Criteria.
-
Delayed prostate-specific antigen recurrence after radical prostatectomy: how to identify and what are their clinical outcomes?
-
Deletion of the p16INK4a tumor suppressor and expression of the androgen receptor induce sarcomatoid carcinomas with signet ring cells in the mouse prostate.
-
Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research.
-
Deregulated PP1α phosphatase activity towards MAPK activation is antagonized by a tumor suppressive failsafe mechanism.
-
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.
-
Design of FRESH START: a randomized trial of exercise and diet among cancer survivors.
-
Design of the North Carolina Prostate Cancer Comparative Effectiveness and Survivorship Study (NC ProCESS).
-
Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT).
-
Detection of human papillomavirus in the prostate by polymerase chain reaction and in situ hybridization.
-
Detection of metastatic tumors in nude mice: brief communication.
-
Detection of oncornavirus antigenic activity in human urothelial tissues.
-
Detection of previously unidentified metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic, castration resistant prostate cancer.
-
Detection of prostate cancer with multiparametric MRI (mpMRI): effect of dedicated reader education on accuracy and confidence of index and anterior cancer diagnosis.
-
Determining optimal prostate-specific antigen thresholds to identify an increased 4-year risk of prostate cancer development: an analysis within the Veterans Affairs Health Care System.
-
Developing a claim-based version of the ACE-27 comorbidity index: a comparison with medical record review.
-
Development and clinical evaluation of a three-dimensional cone-beam computed tomography estimation method using a deformation field map.
-
Development and clinical validation of a real-time PCR assay for PITX2 DNA methylation to predict prostate-specific antigen recurrence in prostate cancer patients following radical prostatectomy.
-
Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer.
-
Development of a Metastatic Spinal Tumor Frailty Index (MSTFI) Using a Nationwide Database and Its Association with Inpatient Morbidity, Mortality, and Length of Stay After Spine Surgery.
-
Development of a Standardized Set of Patient-centered Outcomes for Advanced Prostate Cancer: An International Effort for a Unified Approach.
-
Development of a method to isolate circulating tumor cells using mesenchymal-based capture.
-
Development of a small-molecule serum- and glucocorticoid-regulated kinase-1 antagonist and its evaluation as a prostate cancer therapeutic.
-
Development of an integrated prostate cancer research information system.
-
Dexamethasone suppresses DU145 cell proliferation and cell cycle through inhibition of the extracellular signal-regulated kinase 1/2 pathway and cyclin D1 expression.
-
Diagnosis and Management of Local Recurrence After Prostate Focal Therapy: Challenges and Solutions.
-
Diagnostic accuracy of prostate needle biopsy.
-
Diagnostic potential of prostate-specific antigen expressing epithelial cells in blood of prostate cancer patients.
-
Diet and exercise intervention adherence and health-related outcomes among older long-term breast, prostate, and colorectal cancer survivors.
-
Dietary calcium and risk for prostate cancer: a case-control study among US veterans.
-
Dietary inflammatory index (DII) and risk of prostate cancer in a case-control study among Black and White US Veteran men.
-
Dietary patterns differ between urban and rural older, long-term survivors of breast, prostate, and colorectal cancer and are associated with body mass index.
-
Differences in baseline characteristics and outcomes at 1- and 2-year follow-up of cancer survivors accrued via self-referral versus cancer registry in the FRESH START Diet and exercise trial.
-
Differential effects of prostate cancer therapeutics on neuroendocrine transdifferentiation.
-
Differential immunoreactivity of epidermal growth factor receptor in benign, dysplastic and malignant prostatic tissues.
-
Differential immunoreactivity of her-2/neu oncoprotein in prostatic tissues.
-
Differential immunoreactivity of transforming growth factor alpha in benign, dysplastic and malignant prostatic tissues.
-
Digital tomosynthesis with an on-board kilovoltage imaging device.
-
Dipeptidyl peptidase IV (DPP IV/CD26) is a cell-surface plasminogen receptor.
-
Direct measurement of peptide-specific CD8+ T cells using HLA-A2:Ig dimer for monitoring the in vivo immune response to a HER2/neu vaccine in breast and prostate cancer patients.
-
Diseases of the prostate.
-
Disparate results between proliferation rates of surgically excised prostate tumors and an in vitro bioassay using sera from a positive randomized controlled trial.
-
Disparities in hospitalization outcomes among African-American and White prostate cancer patients.
-
Dissecting the dynamics of serum prostate-specific antigen.
-
Disseminated intravascular coagulation complicating Ender's nailing of a pathologic fracture in prostatic carcinoma. A case report.
-
Diverse genetic-driven immune landscapes dictate tumor progression through distinct mechanisms.
-
Do all men with pathological Gleason score 8-10 prostate cancer have poor outcomes? Results from the SEARCH database.
-
Do patients consistently report comorbid conditions over time?: results from the prostate cancer outcomes study.
-
Do the current subclassifications of stage T3 adenocarcinoma of the prostate have clinical relevance?
-
Do the results of systematic biopsies predict outcome in patients with T1-T2 prostate cancer treated with radiation therapy alone?
-
Docetaxel Resistance in Prostate Cancer: Taking It Up a Notch.
-
Docetaxel for advanced prostate cancer: how early to start?
-
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
-
Does Early Prostate Specific Antigen Doubling Time after Radical Prostatectomy, Calculated Prior to Prostate Specific Antigen Recurrence, Correlate with Prostate Cancer Outcomes? A Report from the SEARCH Database Group.
-
Does MRI-guided TULSA provide a targeted approach to ablation?
-
Does Obesity Modify the Ability of Prebiopsy Prostate Specific Antigen to Detect Prostate Cancer on Repeat Biopsy? Results from the REDUCE Study.
-
Does Peak Urine Flow Rate Predict the Development of Incident Lower Urinary Tract Symptoms in Men with Mild to No Current Symptoms? Results from REDUCE.
-
Does a delay in initiating definitive therapy affect biochemical recurrence rates in men with clinically localized prostate cancer?
-
Does body mass index have an impact on the rate and location of positive surgical margins following robot assisted radical prostatectomy?
-
Does larger tumor volume explain the higher prostate specific antigen levels in black men with prostate cancer--Results from the SEARCH database.
-
Does mpMRI improve clinical criteria in selecting men with prostate cancer for active surveillance?
-
Does preoperative topical antimicrobial scrub reduce positive surgical site culture rates in men undergoing artificial urinary sphincter placement?
-
Does prior benign prostate biopsy predict outcome for patients treated with radical perineal prostatectomy?
-
Does prostate transitional cell carcinoma preclude orthotopic bladder reconstruction after radical cystoprostatectomy for bladder cancer?
-
Does radical prostatectomy in the presence of positive pelvic lymph nodes enhance survival?
-
Does the multidisciplinary approach improve oncological outcomes in men undergoing surgical treatment for prostate cancer?
-
Does transurethral resection of the prostate promote metastatic disease?
-
Does variation in either age at start of therapy or duration of therapy make chemoprevention with finasteride cost-effective?
-
Dosimetric and geometric evaluation of a hybrid strategy of offline adaptive planning and online image guidance for prostate cancer radiotherapy.
-
Dosimetric and radiobiologic comparison of 3D conformal versus intensity modulated planning techniques for prostate bed radiotherapy.
-
Dosimetric comparison of four target alignment methods for prostate cancer radiotherapy.
-
Dosimetric effect of intrafraction motion and residual setup error for hypofractionated prostate intensity-modulated radiotherapy with online cone beam computed tomography image guidance.
-
Dosimetric feasibility of cone-beam CT-based treatment planning compared to CT-based treatment planning.
-
Dosimetric quantifiers for low-dose-rate prostate brachytherapy: is V(100) superior to D(90)?
-
Dosimetry and cancer control after low-dose-rate prostate brachytherapy.
-
Down-regulation of neu/HER-2 by interferon-gamma in prostate cancer cells.
-
Drug development in prostate cancer: time to embrace RECIST?
-
Dunning rat prostate adenocarcinomas and alternative splicing reporters: powerful tools to study epithelial plasticity in prostate tumors in vivo.
-
Dynamic prediction of metastases after radical prostatectomy for prostate cancer.
-
ELF3 is a repressor of androgen receptor action in prostate cancer cells.
-
Early onset baldness and prostate cancer risk.
-
Early prostate cancer: prevention, treatment modalities, and quality of life issues.
-
Early prostate cancer: the national results of radiation treatment from the Patterns of Care and Radiation Therapy Oncology Group studies with prospects for improvement with conformal radiation and adjuvant androgen deprivation.
-
Early quality of life assessment in men treated with permanent source interstitial brachytherapy for clinically localized prostate cancer.
-
Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy.
-
Early-Life Alcohol Intake and High-Grade Prostate Cancer: Results from an Equal-Access, Racially Diverse Biopsy Cohort.
-
Editorial Comment on "Prevalence of Prostate Cancer in PI-RADS Version 2.1 Transition Zone Atypical Nodules Upgraded by Abnormal DWI: Correlation With MRI-Directed TRUS-Guided Targeted Biopsy".
-
Editorial Comment.
-
Editorial Comment.
-
Editorial Comment.
-
Editorial Comment.
-
Editorial comment on: Development of a new method for monitoring prostate-specific antigen changes in men with localised prostate cancer: a comparison of observational cohorts.
-
Editorial comment.
-
Editorial comment.
-
Editorial comment.
-
Editorial comment.
-
Editorial comment.
-
Editorial comment.
-
Editorial comment.
-
Editorial comment.
-
Editorial comment.
-
Editorial comment.
-
Editorial comment.
-
Editorial comment. Acute lower urinary tract symptoms after prostate brachytherapy with cesium-131.
-
Editorial comment. Which patients with undetectable PSA levels 5 years after radical prostatectomy are still at risk of recurrence?--Implications for a risk-adapted follow-up strategy.
-
Effect of Androgen Deprivation Therapy on Metabolic Complications and Cardiovascular Risk.
-
Effect of a metalloporphyrin antioxidant (MnTE-2-PyP) on the response of a mouse prostate cancer model to radiation.
-
Effect of age and pathologic Gleason score on PSA recurrence: analysis of 2911 patients undergoing radical prostatectomy.
-
Effect of age on biochemical disease-free outcome in patients with T1-T3 prostate cancer treated with definitive radiotherapy in an equal-access health care system: a radiation oncology report of the Department of Defense Center for Prostate Disease Research.
-
Effect of flaxseed supplementation on prostatic carcinoma in transgenic mice.
-
Effect of hormones on the growth of virus-transformed hamster prostatic tissue.
-
Effect of low-fat diets on plasma levels of NF-κB-regulated inflammatory cytokines and angiogenic factors in men with prostate cancer.
-
Effect of physician disclosure of specialty bias on patient trust and treatment choice.
-
Effect of positive end-expiratory pressure on blood loss during retropubic and robot-assisted laparoscopic radical prostatectomy.
-
Effect of race on biochemical disease-free outcome in patients with prostate cancer treated with definitive radiation therapy in an equal-access health care system: radiation oncology report of the Department of Defense Center for Prostate Disease Research.
-
Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT).
-
Effect of the first day correction on systematic setup error reduction.
-
Effect of the somatostatin analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: results of a phase II study.
-
Effect of zoledronic acid on pain associated with bone metastasis in patients with prostate cancer.
-
Effective treatment of experimental DU-145 prostate cancers with targeted cytotoxic somatostatin analog AN-238.
-
Effects of family history and genetic polymorphism on the cost-effectiveness of chemoprevention with finasteride for prostate cancer.
-
Effects of home-based diet and exercise on functional outcomes among older, overweight long-term cancer survivors: RENEW: a randomized controlled trial.
-
Effects of neoadjuvant hormonal therapy on prostate biopsy results after (125)I and (103)Pd seed implantation.
-
Effects of nonlinear aerobic training on erectile dysfunction and cardiovascular function following radical prostatectomy for clinically localized prostate cancer.
-
Effects of physical and mental health on relationship satisfaction: a dyadic, longitudinal examination of couples facing prostate cancer.
-
Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer.
-
Efficacy of antisense morpholino oligomer targeted to c-myc in prostate cancer xenograft murine model and a Phase I safety study in humans.
-
Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials.
-
Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: results of Cancer and Leukemia Group B (CALGB) 9782.
-
Efficient gene transfer with adeno-associated virus-based plasmids complexed to cationic liposomes for gene therapy of human prostate cancer.
-
Elective irradiation of pelvic lymph nodes during postprostatectomy salvage radiotherapy.
-
Elevated body mass index predicts for longer overall survival duration in men with metastatic hormone-refractory prostate cancer.
-
Elevated expression of PCGEM1, a prostate-specific gene with cell growth-promoting function, is associated with high-risk prostate cancer patients.
-
Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer.
-
Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy.
-
Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group.
-
Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.
-
Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer.
-
Emerging treatment options for patients with castration-resistant prostate cancer.
-
Endocrine effects, efficacy and tolerability of a 10.8-mg depot formulation of goserelin acetate administered every 13 weeks to patients with advanced prostate cancer.
-
Enhanced oncolytic activity of vesicular stomatitis virus encoding SV5-F protein against prostate cancer.
-
Ensuring comprehensive assessment of urinary problems in prostate cancer through patient-physician concordance.
-
Enzalutamide in metastatic prostate cancer before chemotherapy.
-
Epac1-induced cellular proliferation in prostate cancer cells is mediated by B-Raf/ERK and mTOR signaling cascades.
-
EphrinA I-targeted nanoshells for photothermal ablation of prostate cancer cells.
-
Epidemiology and screening for prostate cancer.
-
Epidemiology of radical prostatectomy for localized prostate cancer in the era of prostate-specific antigen: an overview of the Department of Defense Center for Prostate Disease Research national database.
-
Epidermal growth factor receptor gene analysis in renal cell carcinoma.
-
Epidermal growth factor receptor signaling promotes metastatic prostate cancer through microRNA-96-mediated downregulation of the tumor suppressor ETV6.
-
Epithelial-mesenchymal transition in prostate cancer: providing new targets for therapy.
-
Equivalent uniform dose, D(90), and V(100) correlation with biochemical control after low-dose-rate prostate brachytherapy for clinically low-risk prostate cancer.
-
Erectile function outcome reporting after clinically localized prostate cancer treatment.
-
Erythropoietin and erythropoietin receptor expression in human prostate cancer.
-
Establishing the distribution of satellite lesions in intermediate- and high-risk prostate cancer: implications for focused radiotherapy.
-
Establishment and characterization of a new human prostatic carcinoma cell line (DuPro-1).
-
Etoposide in prostatic cancer: experimental studies and phase II trial in patients with bidimensionally measurable disease.
-
Evaluating measurement invariance across assessment modes of phone interview and computer self-administered survey for the PROMIS measures in a population-based cohort of localized prostate cancer survivors.
-
Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer.
-
Evaluation and Active Treatment versus Active Surveillance of Localized Prostate Cancer in Renal Transplant Patients in the Era of Low and Very Low Risk Prostate Cancer.
-
Evaluation of a commercial DIR platform for contour propagation in prostate cancer patients treated with IMRT/VMAT.
-
Evaluation of a contour-alignment technique for CT-guided prostate radiotherapy: an intra- and interobserver study.
-
Evaluation of a novel precision template-guided biopsy system for detecting prostate cancer.
-
Evaluation of an artificial intelligence guided inverse planning system: clinical case study.
-
Evaluation of an epithelial plasticity biomarker panel in men with localized prostate cancer.
-
Evaluation of cathepsin D and epidermal growth factor receptor in prostate carcinoma.
-
Evaluation of ligand-dependent changes in AR structure using peptide probes.
-
Evaluation of multiple image-based modalities for image-guided radiation therapy (IGRT) of prostate carcinoma: a prospective study.
-
Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility.
-
Evaluation of the paracrine and endocrine effects of genitourinary tumor produced growth factors.
-
Evaluations of an adaptive planning technique incorporating dose feedback in image-guided radiotherapy of prostate cancer.
-
Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation.
-
Evidence Synthesis to Accelerate and Improve the Evaluation of Therapies for Metastatic Hormone-sensitive Prostate Cancer.
-
Evidence for Feedback Regulation Following Cholesterol Lowering Therapy in a Prostate Cancer Xenograft Model.
-
Evidence for a novel hybrid immunotoxin recognizing ricin A-chain by one antigen-combining site and a prostate-restricted antigen by the remaining antigen-combining site: potential for immunotherapy.
-
Evidence for a pro-proliferative feedback loop in prostate cancer: the role of Epac1 and COX-2-dependent pathways.
-
Evidence for an alternative glycolytic pathway in rapidly proliferating cells.
-
Evidence of increased failure in the treatment of prostate carcinoma patients who have perineural invasion treated with three-dimensional conformal radiation therapy.
-
Evolution of the concept of focal therapy for prostate cancer.
-
Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer.
-
Ex vivo expanded human Vgamma9Vdelta2+ gammadelta-T cells mediate innate antitumor activity against human prostate cancer cells in vitro.
-
Exercise among breast and prostate cancer survivors--what are their barriers?
-
Exercise as treatment for androgen deprivation therapy-associated physical dysfunction: ready for prime time?
-
Exercise modulation of the host-tumor interaction in an orthotopic model of murine prostate cancer.
-
Experience with Gleason's histopathologic grading in prostatic cancer.
-
Exploiting DNA damage without repair: The activity of platinum chemotherapy in BRCA-mutated prostate cancers.
-
Exploring cancer support needs for older African-American men with prostate cancer.
-
Exploring health behaviors, quality of life, and support needs in African-American prostate cancer survivors: a pilot study to support future interventions.
-
Exploring the Margin Recipe for Online Adaptive Radiation Therapy for Intermediate-Risk Prostate Cancer: An Intrafractional Seminal Vesicles Motion Analysis.
-
Expression characteristics of prostate-derived Ets factor support a role in breast and prostate cancer progression.
-
Expression of androgen and estrogen related proteins in normal weight and obese prostate cancer patients.
-
Expression of the c-erbB-2 (HER-2/neu) oncoprotein in human prostatic carcinoma.
-
Expression profile of an androgen regulated prostate specific homeobox gene NKX3.1 in primary prostate cancer.
-
Extant health behaviors and uptake of standardized vs tailored health messages among cancer survivors enrolled in the FRESH START trial: a comparison of fighting-spirits vs fatalists.
-
Extended field radiation therapy versus delayed hormonal therapy in node positive prostatic adenocarcinoma.
-
Extended release, 6-month formulations of leuprolide acetate for the treatment of advanced prostate cancer: achieving testosterone levels below 20 ng/dl.
-
External beam radiation therapy after radical prostatectomy: efficacy and impact on urinary continence.
-
External beam radiation therapy for clinically localized prostate cancer: when and how we optimize with concurrent hormonal deprivation.
-
External validation of the SEARCH model for predicting aggressive recurrence after radical prostatectomy: results from the Duke Prostate Center Database.
-
Extreme hypofractionation for prostate cancer.
-
FOXA2 is a sensitive and specific marker for small cell neuroendocrine carcinoma of the prostate.
-
FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonist.
-
Facilitating research participation and improving quality of life for African American prostate cancer survivors and their intimate partners. A pilot study of telephone-based coping skills training.
-
Factors Affecting Quality of Life at Different Intervals After Treatment of Localized Prostate Cancer: Unique Influence of Treatment Decision Making Satisfaction, Personality and Sexual Functioning.
-
Factors associated with appropriate and low-value PSA testing.
-
Factors associated with blood loss during radical prostatectomy for localized prostate cancer in the prostate-specific antigen (PSA)-era: an overview of the Department of Defense (DOD) Center for Prostate Disease Research (CPDR) national database.
-
Factors influencing phenotypic diversity of human prostate carcinoma cells metastasizing in athymic nude mice.
-
Factors predicting early and late phase decline of sexual health-related quality of life following radical prostatectomy.
-
Factors predicting prostatic biopsy Gleason sum under grading.
-
False-Positive Pancreatic Uptake Detected on 68Ga-PSMA PET/CT: A Priority Changing Incidental Finding While Assessing the Need for a Prostate Biopsy.
-
Fascin regulates prostate cancer cell invasion and is associated with metastasis and biochemical failure in prostate cancer.
-
Feasibility, acceptability and preliminary psychological benefits of mindfulness meditation training in a sample of men diagnosed with prostate cancer on active surveillance: results from a randomized controlled pilot trial.
-
Fenretinide: induction of apoptosis and endogenous transforming growth factor beta in PC-3 prostate cancer cells.
-
Financial comparative analysis of minimally invasive surgery to open surgery for localized prostate cancer: a single-institution experience.
-
Finasteride and bicalutamide as primary hormonal therapy in patients with advanced adenocarcinoma of the prostate.
-
Finding a Needle in the Haystack: The Search for Germline Variants Associated with Prostate Cancer Clinical Outcomes.
-
First postoperative PSA is associated with outcomes in patients with node positive prostate cancer: Results from the SEARCH database.
-
First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients.
-
First-in-man evaluation of 2 high-affinity PSMA-avid small molecules for imaging prostate cancer.
-
First-year weight loss with androgen-deprivation therapy increases risks of prostate cancer progression and prostate cancer-specific mortality: results from SEARCH.
-
Fish oil slows prostate cancer xenograft growth relative to other dietary fats and is associated with decreased mitochondrial and insulin pathway gene expression.
-
Fitting NTCP models to bladder doses and acute urinary symptoms during post-prostatectomy radiotherapy.
-
Five-Year Biochemical Progression-Free Survival Following Salvage Whole-Gland Prostate Cryoablation: Defining Success with Nadir Prostate-Specific Antigen.
-
Flaxseed supplementation (not dietary fat restriction) reduces prostate cancer proliferation rates in men presurgery.
-
Flaxseed-derived enterolactone is inversely associated with tumor cell proliferation in men with localized prostate cancer.
-
Flow cytometric analysis of comedocarcinoma of the prostate: an uncommon histopathological variant of prostatic adenocarcinoma.
-
Flow cytometric determination of ploidy in prostatic adenocarcinoma: a comparison with seminal vesicle involvement and histopathological grading as a predictor of clinical recurrence.
-
Foamy gland adenocarcinoma of the prostate: incidence, Gleason grade, and early clinical outcome.
-
Focal Cryotherapy for Localized Prostate Cancer.
-
Focal Laser Ablation of Prostate Cancer: Phase I Clinical Trial.
-
Focal Therapy Eligibility Determined by Magnetic Resonance Imaging/Ultrasound Fusion Biopsy.
-
Focal Therapy for Prostate Cancer: A More Vehement View of the Approach Could Translate into Real Benefits for Our Patients.
-
Focal cryotherapy for prostate cancer.
-
Focal laser ablation as clinical treatment of prostate cancer: report from a Delphi consensus project.
-
Focal therapy for prostate and renal cancer--are we ready for it?
-
Focal therapy for prostate cancer is a reasonable treatment option in properly selected patients.
-
Focal therapy for prostate cancer.
-
Focal therapy for prostate cancer: pathologic basis.
-
Focal therapy for prostate cancer: possibilities and limitations.
-
Focal therapy in prostate cancer-report from a consensus panel.
-
Focal therapy of prostate and kidney cancer.
-
Focal therapy of prostate cancer: evidence-based analysis for modern selection criteria.
-
Focal therapy of prostate cancer: making steady progress toward a first-line image-guided treatment modality.
-
Focal therapy: patients, interventions, and outcomes--a report from a consensus meeting.
-
Focusing on testosterone.
-
Follow-up modalities in focal therapy for prostate cancer: results from a Delphi consensus project.
-
Fostering informed decisions: a randomized controlled trial assessing the impact of a decision aid among men registered to undergo mass screening for prostate cancer.
-
Fraction of positive cores in prostate needle biopsy is significantly predictive of pathological stage in radical prostatectomy.
-
Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers.
-
Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome.
-
From whole-gland to targeted cryoablation for the treatment of unilateral or focal prostate cancer.
-
Frontiers in Genitourinary Pathology.
-
Functional status declines among cancer survivors: trajectory and contributing factors.
-
Gastrointestinal toxicity of transperineal interstitial prostate brachytherapy.
-
Gefitinib (Iressa, ZD1839) and tyrosine kinase inhibitors: the wave of the future in cancer therapy.
-
Gene therapy for prostate cancer.
-
Gene therapy for prostate cancer.
-
Gene therapy for prostate cancer: where are we now?
-
Genetic alterations in prostate adenocarcinoma.
-
Genetic factors influencing prostate cancer risk in Norwegian men.
-
Genetic variants in the TEP1 gene are associated with prostate cancer risk and recurrence.
-
Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types.
-
Genome-wide linkage of 77 families from the African American Hereditary Prostate Cancer study (AAHPC).
-
Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.
-
Genomic Scores are Independent of Disease Volume in Men with Favorable Risk Prostate Cancer: Implications for Choosing Men for Active Surveillance.
-
Geographic Differences in Baseline Prostate Inflammation and Relationship with Subsequent Prostate Cancer Risk: Results from the Multinational REDUCE Trial.
-
Geometric and dosimetric evaluations of an online image-guidance strategy for 3D-CRT of prostate cancer.
-
Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium.
-
Germline mutations in PPFIBP2 are associated with lethal prostate cancer.
-
Gleason Grading, Biochemical Failure, and Prostate Cancer-Specific Death.
-
Gli Transcription Factors Mediate the Oncogenic Transformation of Prostate Basal Cells Induced by a Kras-Androgen Receptor Axis.
-
Glucocorticoids manifest androgenic activity in a cell line derived from a metastatic prostate cancer.
-
Glutathione and glutathione S-transferase in benign and malignant prostate cell lines and prostate tissues.
-
Glutathione depletion increases the cytotoxicity of melphalan to PC-3, an androgen-insensitive prostate cancer cell line.
-
Gold nanoshell-localized photothermal ablation of prostate tumors in a clinical pilot device study.
-
Gonadotropin-releasing hormone agonist overuse: urologists' response to reimbursement and characteristics associated with persistent overuse.
-
Grade-specific prostate cancer associations of IGF1 (CA)19 repeats and IGFBP3-202A/C in blacks and whites.
-
Group trajectory analysis helps to identify older cancer survivors who benefit from distance-based lifestyle interventions.
-
Guideline for the management of clinically localized prostate cancer: 2007 update.
-
Gα-13 induces CXC motif chemokine ligand 5 expression in prostate cancer cells by transactivating NF-κB.
-
HEPSIN inhibits cell growth/invasion in prostate cancer cells.
-
HOXB13 interaction with MEIS1 modifies proliferation and gene expression in prostate cancer.
-
Health-related quality of life in men receiving prostate brachytherapy on RTOG 98-05.
-
Heat shock protein 70 (HSP70) does not prevent the inhibition of cell growth in DU-145 cells treated with TGF-beta1.
-
Helping patients with localized prostate carcinoma manage uncertainty and treatment side effects: nurse-delivered psychoeducational intervention over the telephone.
-
Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma.
-
Hereditary link: scientists seek clues in genetic risks for prostate cancer.
-
Hereditary prostate cancer in African-American families.
-
Heterotransplantation of a human prostatic adenocarcinoma cell line in nude mice.
-
High Dimensional Variable Selection with Error Control.
-
High expression of somatostatin receptors and messenger ribonucleic acid for its receptor subtypes in organ-confined and locally advanced human prostate cancers.
-
High-intensity focused ultrasound for focal therapy: reality or pitfall?
-
High-intensity focused ultrasound for prostate cancer: comparative definitions of biochemical failure.
-
High-resolution microrheology in the pericellular matrix of prostate cancer cells.
-
High-risk prostate cancer and radical prostatectomy in the setting and context of multidisciplinary care.
-
High-volume providers and brachytherapy practice: A Medicare provider utilization and payment analysis.
-
Higher doses of mitoxantrone among men with hormone-refractory prostate carcinoma: a Cancer and Leukemia Group B study.
-
Highlights in advanced prostate cancer from the 2014 AUA and ASCO meetings.
-
Highlights in advanced prostate cancer from the 2014 American Society of Clinical Oncology genitourinary cancers symposium: commentary.
-
Histologic grade, DNA ploidy, and intraglandular tumor extent as indicators of tumor progression of clinical stage B prostatic carcinoma. A direct comparison.
-
Histologic grading as predictor of response to chemotherapy in patients with prostatic adenocarcinoma.
-
Hormonal therapy options for biochemical recurrence of prostate cancer after local therapy.
-
Hormonal therapy options for prostate-specific antigen-only recurrence of prostate cancer after previous local therapy.
-
Hormone naïve prostate cancer: predicting and maximizing response intervals.
-
Hormone refractory prostate cancer: Management and advances.
-
Hot topic of cancer survivorship and the 'seven deadly sins'.
-
How and why a generation of radiologists must be trained to accurately interpret prostate mpMRI.
-
How does sipuleucel-T alter our clinical practice?
-
Human CDK12 and CDK13, multi-tasking CTD kinases for the new millenium.
-
Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro.
-
Human papillomavirus types 16 and 18 are not involved in human prostate carcinogenesis: analysis of archival human prostate cancer specimens by differential polymerase chain reaction.
-
Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.
-
Hypercholesterolemia and prostate cancer: a hospital-based case-control study.
-
Hypoexpression and epigenetic regulation of candidate tumor suppressor gene CADM-2 in human prostate cancer.
-
Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO and AUA Evidence-Based Guideline.
-
Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO, and AUA Evidence-Based Guideline.
-
Hypofractionation for clinically localized prostate cancer.
-
Hypofractionation for prostate cancer: a critical review.
-
Hypofractionation for prostate cancer: tested and proven.
-
Hypophosphatemic osteomalacia: association with prostatic carcinoma.
-
IFNalpha induces the expression of the cyclin-dependent kinase inhibitor p21 in human prostate cancer cells.
-
IFNgamma induction of p21WAF1 in prostate cancer cells: role in cell cycle, alteration of phenotype and invasive potential.
-
IGF1 (CA)19 repeat and IGFBP3 -202 A/C genotypes and the risk of prostate cancer in Black and White men.
-
Identification and Functional Validation of Reciprocal microRNA-mRNA Pairings in African American Prostate Cancer Disparities.
-
Identification of a genetic signature of activated signal transducer and activator of transcription 3 in human tumors.
-
Identification of differentially methylated genes in normal prostate tissues from African American and Caucasian men.
-
Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate.
-
Identifying Clinically Significant Prostate Cancers using 3-D In Vivo Acoustic Radiation Force Impulse Imaging with Whole-Mount Histology Validation.
-
Identifying appropriate patients for early salvage radiotherapy after prostatectomy.
-
Illness uncertainty, partner support, and quality of life: A dyadic longitudinal investigation of couples facing prostate cancer.
-
Image Guided Hypofractionated Postprostatectomy Intensity Modulated Radiation Therapy for Prostate Cancer.
-
Imaging alternative splicing in living cells.
-
Immunohistologic detection of prostate cancer pelvic lymph node micrometastases: correlation to preoperative serum prostate-specific antigen.
-
Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer.
-
Impact of Late Dosing on Testosterone Suppression with 2 Different Leuprolide Acetate Formulations: In Situ Gel and Microsphere. An Analysis of United States Clinical Data.
-
Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy.
-
Impact of carbohydrate restriction in the context of obesity on prostate tumor growth in the Hi-Myc transgenic mouse model.
-
Impact of comorbidity on health-related quality of life after prostate cancer treatment: combined analysis of two prospective cohort studies.
-
Impact of diagnosis and treatment of clinically localized prostate cancer on health-related quality of life for older Americans: a population-based study.
-
Impact of patient navigation on timely cancer care: the Patient Navigation Research Program.
-
Impact of pelvic lymphadenectomy in patients with prostatic adenocarcinoma.
-
Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death.
-
Impact of primary Gleason grade on risk stratification for Gleason score 7 prostate cancers.
-
Impact of race on survival in men with metastatic hormone-refractory prostate cancer.
-
Impact of radical prostatectomy in the management of clinically localized disease.
-
Impact of socioeconomic status and race on clinical parameters of patients undergoing radical prostatectomy in an equal access health care system.
-
Impact of undergoing prostate carcinoma screening on prostate carcinoma-related knowledge and distress.
-
Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019.
-
Implementation of a web-based prostate cancer decision site.
-
Importance of serum hemoglobin in hormone refractory prostate cancer.
-
Improved accuracy of apparent diffusion coefficient quantification using a fully automatic noise bias compensation method: Preliminary evaluation in prostate diffusion weighted imaging.
-
Improved antitumor activity of a recombinant anti-Lewis(y) immunotoxin not requiring proteolytic activation.
-
Improved prostate cancer-specific survival and other disease parameters: impact of prostate-specific antigen testing.
-
Improvement in prostate cancer survival over time: a 20-year analysis: the Will Rogers phenomenon returns.
-
Improvements in pathologic staging for African-American men undergoing radical retropubic prostatectomy during the prostate specific antigen era: implications for screening a high-risk group for prostate carcinoma.
-
Improvements in prostate radiotherapy from the customization of beam directions.
-
In Men with Castration-Resistant Prostate Cancer, Visceral Metastases Predict Shorter Overall Survival: What Predicts Visceral Metastases? Results from the SEARCH Database.
-
In Reply to Fiorino and Cozzarini.
-
In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel? No, not yet.
-
In regard to Brenner et al. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio) similar to late-responding normal tissue.
-
In regard to Ghaly et al., IJROBP 2003;55:1288-1293.
-
In regard to Lee et al.: "Dosimetry and cancer control after low-dose-rate prostate brachytherapy" (Int J Radiat Oncol Biol Phys 2005;61:52-59).
-
In regards to Wallner et al: (125)I versus (103)PD for low-risk prostate cancer: preliminary PSA outcomes from a prospective randomized multicenter trial (Int J Radiat Oncol Biol Phys 2003;57:1297-1303).
-
In vitro synergism between hybrid immunotoxins and chemotherapeutic drugs: relevance to immunotherapy of prostate carcinoma.
-
In vivo bioavailability and pharmacokinetics of a c-MYC antisense phosphorodiamidate morpholino oligomer, AVI-4126, in solid tumors.
-
In vivo inhibition of PC-3 human androgen-independent prostate cancer by a targeted cytotoxic bombesin analogue, AN-215.
-
In vivo regulation of hTERT expression and telomerase activity by androgen.
-
Incidence of and factors related to late complications in conformal and conventional radiation treatment of cancer of the prostate.
-
Increased optical magnification from 2.5x to 4.3x with technical modification lowers the positive margin rate in open radical retropubic prostatectomy.
-
Increased resistance of tumor cells to hyperthermia mediated by integrin-linked kinase.
-
Increased survival with enzalutamide in prostate cancer after chemotherapy.
-
Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: clinical observations.
-
Indications and practice with androgen deprivation therapy.
-
Induction of Kruppel-like factor 5 expression by androgens results in increased CXCR4-dependent migration of prostate cancer cells in vitro.
-
Induction of apoptosis by diethylstilbestrol in hormone-insensitive prostate cancer cells.
-
Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells.
-
Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA.
-
Inferences about prostate intrafraction motion from pre- and posttreatment volumetric imaging.
-
Inflammatory infiltrate (prostatitis) in whole mounted radical prostatectomy specimens from black and white patients is not an etiology for racial difference in prostate specific antigen.
-
Influence of African American race on the association between preoperative biopsy grade group and adverse histopathologic features of radical prostatectomy.
-
Influence of E. coli-induced prostatic inflammation on expression of androgen-responsive genes and transforming growth factor beta 1 cascade genes in rats.
-
Influence of sextant prostate needle biopsy or surgery on the detection and harvest of intact circulating prostate cancer cells.
-
Influence of tumour size on human prostate tumour metastasis in athymic nude mice.
-
Influence of wide excision of the neurovascular bundle(s) on prognosis in men with clinically localized prostate cancer with established capsular penetration.
-
Information content of five nomograms for outcomes in prostate cancer.
-
Informed Decision Making: Assessment of the Quality of Physician Communication about Prostate Cancer Diagnosis and Treatment.
-
Informed consent. From bodily invasion to the seemingly mundane.
-
Infrequent RAS oncogene mutations in human prostate cancer.
-
Inherited Predisposition to Prostate Cancer: From Gene Discovery to Clinical Impact.
-
Inhibition of NF-kappaB1 and NF-kappaB2 activation in prostate cancer cells treated with antibody against the carboxyl terminal domain of GRP78: effect of p53 upregulation.
-
Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analogue AN-238.
-
Inhibition of human chorionic gonadotropin beta-subunit modulates the mitogenic effect of c-myc in human prostate cancer cells.
-
Inhibition of prostate cancer cell growth by second-site androgen receptor antagonists.
-
Inhibition of telomerase is related to the life span and tumorigenicity of human prostate cancer cells.
-
Inhibition of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase pathway induces p53-independent transcriptional regulation of p21(WAF1/CIP1) in human prostate carcinoma cells.
-
Inhibition of the growth of pre-established subcutaneous tumor nodules of human prostate cancer cells by single injection of the recombinant adenovirus p53 expression vector.
-
Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases.
-
Initial clinical assessment of CT-MRI image fusion software in localization of the prostate for 3D conformal radiation therapy.
-
Initial decline in hemoglobin during neoadjuvant hormonal therapy predicts for early prostate specific antigen failure following radiation and hormonal therapy for patients with intermediate and high-risk prostate cancer.
-
Initial prostate specific antigen 1.5 ng/ml or greater in men 50 years old or younger predicts higher prostate cancer risk.
-
Initiation of salvage therapy for prostate cancer.
-
Injectable polypeptide micelles that form radiation crosslinked hydrogels in situ for intratumoral radiotherapy.
-
Insulin-like growth factor binding protein 2: an androgen-dependent predictor of prostate cancer survival.
-
Insulin-like growth factor binding protein-3 induces early apoptosis in malignant prostate cancer cells and inhibits tumor formation in vivo.
-
Integral dose conservation in radiotherapy.
-
Integrated safety data from 4 randomized, double-blind, controlled trials of autologous cellular immunotherapy with sipuleucel-T in patients with prostate cancer.
-
Integration of multiparametric MRI into active surveillance of prostate cancer.
-
Integrin involvement in freeze resistance of androgen-insensitive prostate cancer.
-
Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer.
-
Intensity-modulated radiotherapy optimization with gEUD-guided dose-volume objectives.
-
Interaction of plasminogen with dipeptidyl peptidase IV initiates a signal transduction mechanism which regulates expression of matrix metalloproteinase-9 by prostate cancer cells.
-
Interest in genetic prostate cancer susceptibility testing among african American men.
-
Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis.
-
Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure.
-
Interobserver variability leads to significant differences in quantifiers of prostate implant adequacy.
-
Interplay between exercise and BMI; results from an equal access, racially diverse biopsy study.
-
Interrupted versus Continuous Suturing for Vesicourethral Anastomosis During Radical Prostatectomy: A Systematic Review and Meta-analysis.
-
Interstitial brachytherapy for prostate cancer--just an expensive variant of 'watchful waiting'?
-
Interstitial implant alone or in combination with external beam radiation therapy for intermediate-risk prostate cancer: a survey of practice patterns in the United States.
-
Intracranial metastatic adenocarcinoma of the prostate presenting as visual disturbance.
-
Intraglandular tumor extent and prognosis in prostatic carcinoma: application of a grid method to prostatectomy specimens.
-
Intraoperative and postoperative complications of radical retropubic prostatectomy in a consecutive series of 1,000 cases.
-
Intratumoral inflammation is associated with more aggressive prostate cancer.
-
Inverse correlation between body mass index and clinical outcomes in men with advanced castration-recurrent prostate cancer.
-
Investigating 3D tumor distribution for optimized diagnosis of prostate cancer.
-
Investigating the distribution of prostate cancer using three-dimensional computer simulation.
-
Investigation momentum: the relentless pursuit to resolve uncertainty.
-
Investigation of phosphoprotein signatures of archived prostate cancer tissue specimens via proteomic analysis.
-
In vitro and in vivo evaluation of resveratrol and 3,5-dihydroxy-4'-acetoxy-trans-stilbene in the treatment of human prostate carcinoma and melanoma.
-
Is Body Mass Index the Best Adiposity Measure for Prostate Cancer Risk? Results From a Veterans Affairs Biopsy Cohort.
-
Is Ki67 prognostic for aggressive prostate cancer? A multicenter real-world study.
-
Is NNT AOK?
-
Is PSA related to serum cholesterol and does the relationship differ between black and white men?
-
Is a 3-mm intrafractional margin sufficient for daily image-guided intensity-modulated radiation therapy of prostate cancer?
-
Is clinical stage T2c prostate cancer an intermediate- or high-risk disease?
-
Is grade or stage of primary importance in determining the outcome after radical prostatectomy for disease clinically confined to the prostate?
-
Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy.
-
Is radical prostatectomy appropriate for very-high-risk prostate cancer patients? No.
-
Is the PSA test useless?
-
Is there a role for a low-carbohydrate ketogenic diet in the management of prostate cancer?
-
Isolation of a human prostate carcinoma cell line (DU 145).
-
Ivory vertebra on 18F-sodium fluoride scan: an old sign in a new modality.
-
Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defense Prostate Cancer Clinical Trials Consortium.
-
Keeping an Open Mind About Novel Concepts for Management of Prostate Cancer.
-
Ketoconazole retains activity in patients with docetaxel-refractory prostate cancer.
-
Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy.
-
Knowledge, beliefs, and prior screening behavior among blacks and whites reporting for prostate cancer screening.
-
Knowledge-based IMRT treatment planning for prostate cancer.
-
LIN28B promotes the development of neuroendocrine prostate cancer.
-
LRIG1 is a pleiotropic androgen receptor-regulated feedback tumor suppressor in prostate cancer.
-
Laparoscopic inguinal hernia repair complicates future pelvic oncologic surgery.
-
Laparoscopic intestinal stomas.
-
Late GI and GU complications in the treatment of prostate cancer.
-
Late rectal bleeding following combined X-ray and proton high dose irradiation for patients with stages T3-T4 prostate carcinoma.
-
Late toxicity and biochemical recurrence after external-beam radiotherapy combined with permanent-source prostate brachytherapy: analysis of Radiation Therapy Oncology Group study 0019.
-
Lateral rectal shielding reduces late rectal morbidity following high dose three-dimensional conformal radiation therapy for clinically localized prostate cancer: further evidence for a significant dose effect.
-
Leading the Way in Exercise and Diet (Project LEAD): intervening to improve function among older breast and prostate cancer survivors.
-
Leveraging γ-Glutamyl Transferase To Direct Cytotoxicity of Copper Dithiocarbamates against Prostate Cancer Cells.
-
Lifestyle intervention development study to improve physical function in older adults with cancer: outcomes from Project LEAD.
-
Ligation of cancer cell surface GRP78 with antibodies directed against its COOH-terminal domain up-regulates p53 activity and promotes apoptosis.
-
Ligation of cell surface GRP78 with antibody directed against the COOH-terminal domain of GRP78 suppresses Ras/MAPK and PI 3-kinase/AKT signaling while promoting caspase activation in human prostate cancer cells.
-
Ligation of prostate cancer cell surface GRP78 activates a proproliferative and antiapoptotic feedback loop: a role for secreted prostate-specific antigen.
-
Limitations of tissue microarrays in the evaluation of focal alterations of bcl-2 and p53 in whole mount derived prostate tissues.
-
Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy.
-
Liver and prostate adenocarcinoma: an "estrogen-free" environment?
-
Localized carcinoma of the prostate (stages T1B, T1C, T2, and T3). Review of management with external beam radiation therapy.
-
Localized prostate cancer treated by external-beam radiotherapy alone: serum prostate-specific antigen--driven outcome analysis.
-
Locally advanced (high-risk) prostate cancer. American College of Radiology. ACR Appropriateness Criteria.
-
Long-term dietary outcomes of the FRESH START intervention for breast and prostate cancer survivors.
-
Long-term outcomes of radical prostatectomy with multimodal adjuvant therapy in men with a preoperative serum prostate-specific antigen level > or =50 ng/mL.
-
Long-term outcomes of the FRESH START trial: exploring the role of self-efficacy in cancer survivors' maintenance of dietary practices and physical activity.
-
Long-term physical activity outcomes of home-based lifestyle interventions among breast and prostate cancer survivors.
-
Long-term results of a phase II trial of ultrasound-guided radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (RTOG 98-05).
-
Long-term results of an RTOG Phase II trial (00-19) of external-beam radiation therapy combined with permanent source brachytherapy for intermediate-risk clinically localized adenocarcinoma of the prostate.
-
Longer-term Lipid-lowering Drug Use and Risk of Incident and Fatal Prostate Cancer in Black and White Men in the ARIC Study.
-
Longitudinal Trends in Costs of Palliative Radiation for Metastatic Prostate Cancer.
-
Look and You Will Find It: Practical Considerations for Improving Multidisciplinary Management of Androgen-Deprivation Therapy-Induced Cardiometabolic Toxicity.
-
Loss of EGFR signaling regulated miR-203 promotes prostate cancer bone metastasis and tyrosine kinase inhibitors resistance.
-
Loss of LDAH associated with prostate cancer and hearing loss.
-
Loss of SPDEF and gain of TGFBI activity after androgen deprivation therapy promote EMT and bone metastasis of prostate cancer.
-
Loss of cell surface TFII-I promotes apoptosis in prostate cancer cells stimulated with activated αâ‚‚ -macroglobulin.
-
Loss of heterozygosity of M6P/IGF2R gene is an early event in the development of prostate cancer.
-
Loss of the tumor suppressor, Tp53, enhances the androgen receptor-mediated oncogenic transformation and tumor development in the mouse prostate.
-
Loss of uteroglobin expression in prostate cancer: relationship to advancing grade.
-
Low CD38 Identifies Progenitor-like Inflammation-Associated Luminal Cells that Can Initiate Human Prostate Cancer and Predict Poor Outcome.
-
Low-carbohydrate diets and prostate cancer: how low is "low enough"?
-
Low-dose genistein induces cyclin-dependent kinase inhibitors and G(1) cell-cycle arrest in human prostate cancer cells.
-
Low-risk and very-low-risk prostate cancer: is there a role for focal therapy in the era of active surveillance? Yes, the two approaches complement each other.
-
Low-risk prostate cancer patient: active treatment.
-
Lymph node staging in potentially curable prostatic carcinoma.
-
Lymph node staging of potentially curable prostatic carcinoma.
-
Lysophosphatidic acid promotes survival of androgen-insensitive prostate cancer PC3 cells via activation of NF-kappaB.
-
M-HIFU inhibits tumor growth, suppresses STAT3 activity and enhances tumor specific immunity in a transplant tumor model of prostate cancer.
-
MR imaging in adenocarcinoma of the prostate: interobserver variation and efficacy for determining stage C disease.
-
MYC activity mitigates response to rapamycin in prostate cancer through eukaryotic initiation factor 4E-binding protein 1-mediated inhibition of autophagy.
-
Magnetic Resonance Imaging Underestimation of Prostate Cancer Geometry: Use of Patient Specific Molds to Correlate Images with Whole Mount Pathology.
-
Magnetic resonance imaging features of pubic symphysis urinary fistula with pubic bone osteomyelitis in the treated prostate cancer patient.
-
Magnetic resonance spectroscopic studies of the prostate.
-
Magnetic separation of acoustically focused cancer cells from blood for magnetographic templating and analysis.
-
Main outcomes of the FRESH START trial: a sequentially tailored, diet and exercise mailed print intervention among breast and prostate cancer survivors.
-
Male breast cancer during treatment with leuprolide for prostate cancer.
-
Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017.
-
Management of Postprostatectomy Biochemical Relapse With Salvage Radiotherapy: Results of an International Survey.
-
Management of Prostate Cancer in the Elderly.
-
Management of metastatic prostatic cancer.
-
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.
-
Management of patients with concurrent primary tumors of bladder and prostate.
-
Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology.
-
Management of recurrent prostate cancer after radiotherapy: long-term results from CALGB 9687 (Alliance), a prospective multi-institutional salvage prostatectomy series.
-
Management of the patient with a rising PSA alone.
-
Managing Prostate Cancer Surgical Patients during the COVID-19 Pandemic: A Brief Report of the Duke Cancer Institute's Initial Experience.
-
Managing advanced prostate cancer with Viadur (leuprolide acetate implant).
-
Masculinity beliefs predict psychosocial functioning in African American prostate cancer survivors.
-
Maspin expression profile in human prostate cancer (CaP) and in vitro induction of Maspin expression by androgen ablation.
-
Massive locally extensive prostate cancer.
-
Maximizing outcomes in genitourinary cancers across the treatment continuum.
-
Measurement of affective and activity pain interference using the Brief Pain Inventory (BPI): Cancer and Leukemia Group B 70903.
-
Measuring illness uncertainty in men undergoing active surveillance for prostate cancer.
-
Mediating effects of cancer risk factors on the association between race and cancer incidence: analysis of the NIH-AARP Diet and Health Study.
-
Medical malpractice and prostate brachytherapy.
-
Medical technologies for the diagnosis of prostate cancer.
-
Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras.
-
Men's Eating and Living (MEAL) study (CALGB 70807 [Alliance]): recruitment feasibility and baseline demographics of a randomized trial of diet in men on active surveillance for prostate cancer.
-
Mendelian randomization study of adiposity-related traits and risk of breast, ovarian, prostate, lung and colorectal cancer.
-
Metabolic syndrome-like components and prostate cancer risk: results from the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) study.
-
Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer.
-
Metastatic prostate cancer in a transgenic mouse.
-
Metastatic rhabdomyosarcoma presenting as intracranial hemorrhage: imaging findings.
-
Metformin does not affect risk of biochemical recurrence following radical prostatectomy: results from the SEARCH database.
-
Metformin use and risk of prostate cancer: results from the REDUCE study.
-
MicroRNA-182 and microRNA-200a control G-protein subunit α-13 (GNA13) expression and cell invasion synergistically in prostate cancer cells.
-
Midlife Cardiorespiratory Fitness, Incident Cancer, and Survival After Cancer in Men: The Cooper Center Longitudinal Study.
-
Minimal carcinoma in prostate needle biopsy specimens: diagnostic features and radical prostatectomy follow-up.
-
Mn porphyrins as novel molecular magnetic resonance imaging contrast agents.
-
Mn-porphyrins as novel molecular magnetic resonance imaging contrast agents.
-
Modeling cancer progression via pathway dependencies.
-
Moderators of an uncertainty management intervention: for men with localized prostate cancer.
-
Modernizing the diagnostic and decision-making pathway for prostate cancer.
-
Modified risk stratification grouping using standard clinical and biopsy information for patients undergoing radical prostatectomy: Results from SEARCH.
-
Modulation of the unfolded protein response by GRP78 in prostate cancer.
-
Modulation of the unfolded protein response in prostate cancer cells by antibody-directed against the carboxyl-terminal domain of GRP78.
-
Molecular Profiling to Determine Clonality of Serial Magnetic Resonance Imaging/Ultrasound Fusion Biopsies from Men on Active Surveillance for Low-Risk Prostate Cancer.
-
Molecular Signature to Risk-Stratify Prostate Cancer of Intermediate Risk.
-
Molecular correlates in urine for the obesity and prostatic inflammation of BPH/LUTS patients.
-
Molecular determinants for enzalutamide-induced transcription in prostate cancer.
-
Molecular implications of the antiandrogen withdrawal syndrome.
-
Molecular markers in prostate cancer: the role in preoperative staging.
-
Molecular mechanisms underlying the potentially adverse effects of folate.
-
Monoclonal antibodies to different epitopes on a prostate tumor-associated antigen. Implications for immunotherapy.
-
Monoclonal antibodies to tissue-specific cell surface antigens. I. Characterization of an antibody to a prostate tissue antigen.
-
Monte Carlo calculation of imaging doses from diagnostic multidetector CT and kilovoltage cone-beam CT as part of prostate cancer treatment plans.
-
Morbidity and prostate-specific antigen control of external beam radiation therapy plus low-dose-rate brachytherapy boost for low, intermediate, and high-risk prostate cancer.
-
Morphologic Spectrum of Neuroendocrine Tumors of the Prostate: An Updated Review.
-
Morphologic and immunologic studies of human prostatic carcinoma.
-
Morphological and biochemical studies of virus (SV40) transformed prostatic tissue.
-
Morphology of hypoxia following cryoablation in a prostate cancer murine model: its relationship to necrosis, apoptosis and, microvessel density.
-
Mortality of patients after radical prostatectomy: analysis of recent Medicare claims.
-
Most Gleason 8 Biopsies are Downgraded at Prostatectomy-Does 4 + 4 = 7?
-
Most of patients with localized prostate cancer will be treated in the future? | Opinion: No.
-
Mucinous adenocarcinoma of the prostate.
-
Multi-institutional Evaluation of Elective Nodal Irradiation and/or Androgen Deprivation Therapy with Postprostatectomy Salvage Radiotherapy for Prostate Cancer.
-
Multi-species prostate implant treatment plans incorporating 192Ir and 125I using a Greedy Heuristic based 3D optimization algorithm.
-
Multi-system verification of registrations for image-guided radiotherapy in clinical trials.
-
Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer.
-
Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable-risk localized prostate cancer: results of Cancer and Leukemia Group B 99811.
-
Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer.
-
Multimodal therapy of prostatic cancer.
-
Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial.
-
Multiparametric Prostate MR Imaging: Impact on Clinical Staging and Decision Making.
-
Multiparametric Prostate MR Imaging: Impact on Clinical Staging and Decision Making.
-
Multiparametric prostate MRI: focus on T2-weighted imaging and role in staging of prostate cancer.
-
Multiple drug chemotherapy regimen for patients with hormonally-unresponsive carcinoma of the prostate: a preliminary report.
-
Multiple measures of carcinoma extent versus perineural invasion in prostate needle biopsy tissue in prediction of pathologic stage in a screening population.
-
Multiregional Radiogenomic Assessment of Prostate Microenvironments with Multiparametric MR Imaging and DNA Whole-Exome Sequencing of Prostate Glands with Adenocarcinoma.
-
Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors.
-
Multivariate models as predictors of pathological stage using Gleason score, clinical stage, and serum prostate-specific antigen.
-
Multivariate statistical analysis for pathologist. Part I, The logistic model.
-
Mutational analysis of the TrkA gene in prostate cancer.
-
Mutations in ribonuclease L gene do not occur at a greater frequency in patients with familial prostate cancer compared with patients with sporadic prostate cancer.
-
Mutations of the p16 gene product are rare in prostate cancer.
-
N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells.
-
NADiA ProsVue prostate-specific antigen slope is an independent prognostic marker for identifying men at reduced risk of clinical recurrence of prostate cancer after radical prostatectomy.
-
NADiA ProsVue prostate-specific antigen slope, CAPRA-S, and prostate cancer--specific survival after radical prostatectomy.
-
NCCN Clinical Practice Guidelines Prostate Cancer Early Detection, Version 2.2015.
-
NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016.
-
NCCN clinical practice guidelines in oncology: prostate cancer early detection.
-
NCCN clinical practice guidelines in oncology: prostate cancer.
-
Natural killer cell activity and prostate cancer risk in veteran men undergoing prostate biopsy.
-
Navigating MRI-TRUS fusion biopsy: optimizing the process and avoiding technical pitfalls.
-
Neoadjuvant androgen-deprivation therapy prior to radical prostatectomy: con.
-
Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer.
-
Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: a preliminary report.
-
Neoadjuvant hormone therapy: the Canadian trials.
-
Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer.
-
Nerve-sparing focal cryoablation of prostate cancer.
-
Neuroendocrine cells of prostate cancer: biologic functions and molecular mechanisms.
-
Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes.
-
Neutron-photon treatment: modern day Pyrrhic victory? Regarding Haraf et al. IJROBP 33(1): 3-14; 1995.
-
Neutropenia as a potential pharmacodynamic marker for docetaxel-based chemotherapy in men with metastatic castration-resistant prostate cancer.
-
Neutrophil, lymphocyte and platelet counts, and risk of prostate cancer outcomes in white and black men: results from the SEARCH database.
-
New advances in focal therapy for early stage prostate cancer.
-
New and Established Technology in Focal Ablation of the Prostate: A Systematic Review.
-
New and emerging therapies for bone metastases in genitourinary cancers.
-
New and emerging treatments for advanced prostate cancer.
-
New data, new paradigms for treating patients with prostate cancer. Conclusion.
-
New data, new paradigms for treating patients with prostate cancer: introduction.
-
New data, new paradigms for treating prostate cancer patients--VI: novel hormonal therapy approaches.
-
New drug development in metastatic prostate cancer.
-
New drugs in prostate cancer.
-
New prostate cancer prognostic grade group (PGG): Can multiparametric MRI (mpMRI) accurately separate patients with low-, intermediate-, and high-grade cancer?
-
Nocturia and associated mortality: observational data from the REDUCE trial.
-
Node-positive prostate cancer. American College of Radiology. ACR Appropriateness Criteria.
-
Novel Methods for Reporting of Exercise Dose and Adherence: An Exploratory Analysis.
-
Novel associations of UDP-glucuronosyltransferase 2B gene variants with prostate cancer risk in a multiethnic study.
-
Novel chemotherapies in development for management of castration-resistant prostate cancer.
-
Novel techniques for the treatment of localized prostate cancer: evidence of efficacy?
-
Novel therapeutic approaches to advanced prostate cancer.
-
Novel therapies for the treatment of advanced prostate cancer.
-
Number of Unfavorable Intermediate-Risk Factors Predicts Pathologic Upstaging and Prostate Cancer-Specific Mortality Following Radical Prostatectomy: Results From the SEARCH Database.
-
Nutrition, dietary interventions and prostate cancer: the latest evidence.
-
Obese African-Americans with prostate cancer (T1c and a prostate-specific antigen, PSA, level of <10 ng/mL) have higher-risk pathological features and a greater risk of PSA recurrence than non-African-Americans.
-
Obese men have higher-grade and larger tumors: an analysis of the duke prostate center database.
-
Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases.
-
Obesity and prostate cancer-specific mortality after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
-
Obesity and survival after radical prostatectomy: A 10-year prospective cohort study.
-
Obesity increases the risk for high-grade prostate cancer: results from the REDUCE study.
-
Obesity, risk of biochemical recurrence, and prostate-specific antigen doubling time after radical prostatectomy: results from the SEARCH database.
-
Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer.
-
Objective evaluation of bone metastases in prostate cancer: to what end?
-
Observations of pretreatment prostate-specific antigen doubling time in 107 patients referred for definitive radiotherapy.
-
On model specification and selection of the Cox proportional hazards model.
-
On-line re-optimization of prostate IMRT plans for adaptive radiation therapy.
-
One step forward and two steps back.
-
Open radical retropubic prostatectomy 2007: the true minimally invasive surgery for localized prostate cancer?
-
Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases.
-
Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors.
-
Optimization of conformal radiation treatment of prostate cancer: report of a dose escalation study.
-
Optimization of intensity-modulated radiotherapy plans based on the equivalent uniform dose.
-
Optimized prostate biopsy via a statistical atlas of cancer spatial distribution.
-
Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer.
-
Optimizing treatment for men with advanced prostate cancer: expert recommendations and the multidisciplinary approach.
-
Optimizing veteran-centered prostate cancer survivorship care: study protocol for a randomized controlled trial.
-
Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.
-
Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial.
-
Ornithine Decarboxylase Is Sufficient for Prostate Tumorigenesis via Androgen Receptor Signaling.
-
Osteopontin has a protective role in prostate tumor development in mice.
-
Osteosarcoma after radiotherapy for prostate cancer.
-
Out of the black box: expansion of a theory-based intervention to self-manage the uncertainty associated with active surveillance (AS) for prostate cancer.
-
Outcome for repeated biopsy of the prostate: roles of serum PSA, small atypical glands, and prostatic intraepithelial neoplasia.
-
Outcome profiles of locoregional disease after radical prostatectomy and radiotherapy.
-
Outcome research: prostate cancer databases.
-
Outcomes of Gleason score 10 prostate carcinoma treated by radical prostatectomy.
-
Outlier identification in radiation therapy knowledge-based planning: A study of pelvic cases.
-
Over half of contemporary clinical Gleason 8 on prostate biopsy are downgraded at radical prostatectomy.
-
Overcoming challenges in designing and implementing a phase II randomized controlled trial using a presurgical model to test a dietary intervention in prostate cancer.
-
Overexpression of hMTH in peripheral lymphocytes and risk of prostate cancer: a case-control analysis.
-
Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer.
-
PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS.
-
PCGEM1, a prostate-specific gene, is overexpressed in prostate cancer.
-
PDEF in prostate cancer.
-
PFT-alpha inhibits antibody-induced activation of p53 and pro-apoptotic signaling in 1-LN prostate cancer cells.
-
PMEPA1, an androgen-regulated NEDD4-binding protein, exhibits cell growth inhibitory function and decreased expression during prostate cancer progression.
-
PSA predicts development of incident lower urinary tract symptoms: results from the REDUCE study.
-
PSA progression following radical prostatectomy and radiation therapy: new standards in the new Millennium.
-
PSA thresholds for prostate cancer detection.
-
PSGR, a novel prostate-specific gene with homology to a G protein-coupled receptor, is overexpressed in prostate cancer.
-
PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer.
-
PTEN polymorphism (IVS4) is not associated with risk of prostate cancer.
-
Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer.
-
Pain predicts overall survival in men with metastatic castration-refractory prostate cancer.
-
Palliative radiotherapy for prostate cancer.
-
Pathologic basis of focal therapy for early-stage prostate cancer.
-
Pathologic stage T2a and T2b prostate cancer in the recent prostate-specific antigen era: implications for unilateral ablative therapy.
-
Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy.
-
Pathological T2 sub-divisions as a prognostic factor in the biochemical recurrence of prostate cancer.
-
Pathological outcomes in men with low risk and very low risk prostate cancer: implications on the practice of active surveillance.
-
Pathological upgrading at radical prostatectomy for patients with Grade Group 1 prostate cancer: implications of confirmatory testing for patients considering active surveillance.
-
Patient and family communication during consultation visits: The effects of a decision aid for treatment decision-making for localized prostate cancer.
-
Patient preferences for treatments to delay bone metastases.
-
Patient selection for experimental adjuvant therapy after radical prostatectomy.
-
Patient selection for hemiablative focal therapy of prostate cancer: variables predictive of tumor unilaterality based upon radical prostatectomy.
-
Patient selection for prostate focal therapy in the era of active surveillance: an International Delphi Consensus Project.
-
Patient-physician communication about early stage prostate cancer: analysis of overall visit structure.
-
Patterns of care for elderly men diagnosed with favorable-risk prostate cancer from 2004 to 2008: a population-based analysis.
-
Patterns of inpatient care for prostate cancer in men with spina bifida.
-
Patterns-of-failure analysis of patients with high pretreatment prostate-specific antigen levels treated by radiation therapy: the need for improved systemic and locoregional treatment.
-
Pelvic Complications After Prostate Cancer Radiation Therapy and Their Management: An International Collaborative Narrative Review.
-
Pelvic lymphadenectomy is not essential to staging accuracy in all patients with localized prostate cancer.
-
Penalized likelihood fluence optimization with evolutionary components for intensity modulated radiation therapy treatment planning.
-
Pentosan polysulfate decreases prostate smooth muscle proliferation and extracellular matrix turnover.
-
Peptidyl membrane-interactive molecules are cytotoxic to prostatic cancer cells in vitro.
-
Percent tumor involvement and risk of biochemical progression after radical prostatectomy.
-
Percentage carcinoma as a measure of prostatic tumor size in radical prostatectomy tissues.
-
Percentage of positive biopsies associated with freedom from biochemical recurrence after low-dose-rate prostate brachytherapy alone for clinically localized prostate cancer.
-
Percentage of tumor and tumor length in prostate biopsy specimens: a study of American veterans.
-
Percentage of tumor in prostatectomy specimens: a study of American Veterans.
-
Perception of cancer and inconsistency in medical information are associated with decisional conflict: a pilot study of men with prostate cancer who undergo active surveillance.
-
Performance evaluation of automatic anatomy segmentation algorithm on repeat or four-dimensional computed tomography images using deformable image registration method.
-
Perineal seeding of prostate cancer as the only evidence of clinical recurrence 14 years after needle biopsy and radical prostatectomy: molecular correlation.
-
Permanent source brachytherapy for prostate cancer. American College of Radiology. ACR Appropriateness Criteria.
-
Personalized prediction of tumor response and cancer progression on prostate needle biopsy.
-
Pharmacists as health educators and risk communicators in the early detection of prostate cancer.
-
Pharmacodynamic study of disulfiram in men with non-metastatic recurrent prostate cancer.
-
Pharmacokinetics and radiation dosimetry of 18F-fluorocholine.
-
Pharmacological uncoupling of androgen receptor-mediated prostate cancer cell proliferation and prostate-specific antigen secretion.
-
Phase 1 study of PSMA ADC, an antibody-drug conjugate targeting prostate-specific membrane antigen, in chemotherapy-refractory prostate cancer.
-
Phase 1 trial of neoadjuvant radiation therapy before prostatectomy for high-risk prostate cancer.
-
Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone.
-
Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium.
-
Phase I-II prospective dose-escalating trial of lycopene in patients with biochemical relapse of prostate cancer after definitive local therapy.
-
Phase II randomized trial of weekly paclitaxel with or without estramustine phosphate in progressive, metastatic, hormone-refractory prostate cancer.
-
Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer.
-
Phase II study of azacitidine to restore responsiveness of prostate cancer to hormonal therapy.
-
Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B.
-
Phase II study of etoposide for carcinoma of the prostate.
-
Phase II study of low-dose docetaxel/estramustine in elderly patients or patients aged 18-74 years with hormone-refractory prostate cancer.
-
Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate.
-
Phase II trial of sunitinib for the therapy of progressive metastatic castration-refractory prostate cancer after previous docetaxel chemotherapy.
-
Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer.
-
Phase III trial of selenium to prevent prostate cancer in men with high-grade prostatic intraepithelial neoplasia: SWOG S9917.
-
Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer.
-
Physician Recommendations Trump Patient Preferences in Prostate Cancer Treatment Decisions.
-
Physicians' attitudes about shared decision making for prostate cancer screening.
-
Pilot study of dietary fat restriction and flaxseed supplementation in men with prostate cancer before surgery: exploring the effects on hormonal levels, prostate-specific antigen, and histopathologic features.
-
Pilot study to explore effects of low-fat, flaxseed-supplemented diet on proliferation of benign prostatic epithelium and prostate-specific antigen.
-
Planning, delivery, and quality assurance of intensity-modulated radiotherapy using dynamic multileaf collimator: a strategy for large-scale implementation for the treatment of carcinoma of the prostate.
-
Plasma levels of heat shock protein 70 in patients with prostate cancer: a potential biomarker for prostate cancer.
-
Plasminogen structural domains exhibit different functions when associated with cell surface GRP78 or the voltage-dependent anion channel.
-
Platelet-derived growth factor receptors: a therapeutic target in solid tumors.
-
Point/Counterpoint. Online adaptive planning for prostate cancer radiotherapy is necessary and ready now.
-
Point: radical prostatectomy is the treatment of choice for high-risk prostate cancer patients.
-
Polymer-delivered subcutaneous leuprolide acetate formulations achieve and maintain castrate concentrations of testosterone in four open-label studies in patients with advanced prostate cancer.
-
Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk.
-
Polymorphisms in nucleotide excision repair genes and risk of primary prostate cancer in Chinese Han populations.
-
Polymorphisms in the mTOR gene and risk of sporadic prostate cancer in an Eastern Chinese population.
-
Population screening for prostate cancer and emerging concepts for young men.
-
Positive margins: is adjunctive radiation therapy indicated?
-
Possible mechanism for seeding of tumor during radical prostatectomy.
-
Post-radical prostatectomy management options for positive surgical margins: argument for observation.
-
Postimplant analysis of transperineal interstitial permanent prostate brachytherapy: evidence for a learning curve in the first year at a single institution.
-
Postoperative Radiation Therapy for Prostate Cancer: Comparison of Conventional Versus Hypofractionated Radiation Regimens.
-
Postoperative prostate-specific antigen as a prognostic indicator in patients with margin-positive prostate cancer, undergoing adjuvant radiotherapy after radical prostatectomy.
-
Postoperative prostate-specific antigen nadir improves accuracy for predicting biochemical recurrence after radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) and Duke Prostate Center databases.
-
Postoperative radiation therapy for pathologically advanced prostate cancer after radical prostatectomy.
-
Postoperative radiotherapy of the prostate for patients undergoing radical prostatectomy with positive margins, seminal vesicle involvement and/or penetration through the capsule.
-
Postoperative statin use and risk of biochemical recurrence following radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
-
Postprostatectomy radiation therapy: an evidence-based review.
-
Postradical prostatectomy irradiation in carcinoma of the prostate. American College of Radiology. ACR Appropriateness Criteria.
-
Potential predictive biomarkers for individualizing treatment for men with castration-resistant prostate cancer.
-
Potentiation of signal transduction mitogenesis and cellular proliferation upon binding of receptor-recognized forms of alpha2-macroglobulin to 1-LN prostate cancer cells.
-
Preclinical testing of a peptide-based, HER2/neu vaccine for prostate cancer.
-
Prediagnostic plasma vascular endothelial growth factor levels and risk of prostate cancer.
-
Predicting and monitoring results of therapy.
-
Predicting biopsy-proven prostate cancer recurrence following cryosurgery.
-
Predicting bone scan positivity after biochemical recurrence following radical prostatectomy in both hormone-naive men and patients receiving androgen-deprivation therapy: results from the SEARCH database.
-
Predicting clinical outcome of therapy-resistant prostate cancer.
-
Predicting non-organ-confined prostate cancer in men diagnosed after 2000.
-
Predicting participation in and successful outcome of a penile rehabilitation programme using a phosphodiesterase type 5 inhibitor with a vacuum erection device after radical prostatectomy.
-
Predicting prostate biopsy results: The importance of PSA, age, and race.
-
Predicting prostate cancer mortality among men with intermediate to high-risk disease and multiple unfavorable risk factors.
-
Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases.
-
Predicting the pathology results of radical prostatectomy from preoperative information: a validation study.
-
Predicting tumor failure in prostate carcinoma after definitive radiation therapy: limitations of models based on prostate-specific antigen, clinical stage, and Gleason score.
-
Predicting unilateral prostate cancer based on biopsy features: implications for focal ablative therapy--results from the SEARCH database.
-
Predicting unilateral prostate cancer on routine diagnostic biopsy: sextant vs extended.
-
Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer.
-
Predictive probability of serum prostate-specific antigen for prostate cancer: an approach using Bayes rule.
-
Predictive value of digital rectal examination for prostate cancer detection is modified by obesity.
-
Predictors of Rectourethral Fistula Formation After Primary Whole-Gland Cryoablation for Prostate Cancer: Results from the Cryo On-Line Database Registry.
-
Predictors of adverse smoking outcomes in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
-
Predictors of extracapsular extension and positive margins in African American and white men.
-
Predictors of lymphatic spread in prostatic adenocarcinoma: uro-oncology research group study.
-
Predictors of operative time during radical retropubic prostatectomy and robot-assisted laparoscopic prostatectomy.
-
Predictors of prolonged operative time during robot-assisted laparoscopic radical prostatectomy.
-
Predictors of prostate cancer tissue acquisition by an undirected core bone marrow biopsy in metastatic castration-resistant prostate cancer--a Cancer and Leukemia Group B study.
-
Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy.
-
Preliminary validation of varicella zoster virus thymidine kinase as a novel reporter gene for PET.
-
Preoperative predictors of pathologic stage T2a and pathologic Gleason score ≤ 6 in men with clinical low-risk prostate cancer treated with radical prostatectomy: reference for active surveillance.
-
Preoperative predictors of pathologic stage T2a in low-risk prostate cancer: implications for focal therapy.
-
Presence of receptors for bombesin/gastrin-releasing peptide and mRNA for three receptor subtypes in human prostate cancers.
-
Pretreatment expectations of patients undergoing robotic assisted laparoscopic or open retropubic radical prostatectomy.
-
Pretreatment prostate-specific antigen doubling times: clinical utility of this predictor of prostate cancer behavior.
-
Pretreatment prostate-specific antigen velocity is associated with freedom from biochemical recurrence of prostate cancer after low-dose-rate prostate brachytherapy alone.
-
Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy.
-
Prevalence of erectile dysfunction in men screened for prostate cancer.
-
Prevalence of pain and analgesic use in men with metastatic prostate cancer using a patient-reported outcome measure.
-
Preventing pain during office biopsy of the prostate: a single center, prospective, double-blind, 3-arm, parallel group, randomized clinical trial.
-
Primary Cryotherapy for High-Grade Clinically Localized Prostate Cancer: Oncologic and Functional Outcomes from the COLD Registry.
-
Primary care perspective and implementation of a multidisciplinary, institutional prostate cancer screening algorithm embedded in the electronic health record.
-
Primary care providers' perspectives on discontinuing prostate cancer screening.
-
Primary care providers' response to the US Preventive Services Task Force draft recommendations on screening for prostate cancer.
-
Primary hormonal therapy for prostate cancer: experience with 135 consecutive PSA-ERA patients from a tertiary care military medical center.
-
Process control analysis of IMRT QA: implications for clinical trials.
-
Production of monoclonal antibody alpha Pro3 recognizing a human prostatic carcinoma antigen.
-
Prognosis of patients with stage D1 prostatic adenocarcinoma.
-
Prognostic factors in metastatic and hormonally unresponsive carcinoma of the prostate.
-
Prognostic indicators in hormone refractory prostate cancer.
-
Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.
-
Prognostic significance of DNA ploidy in carcinoma of prostate.
-
Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study.
-
Prognostic significance of plasma scatter factor/hepatocyte growth factor levels in patients with metastatic hormone- refractory prostate cancer: results from cancer and leukemia group B 150005/9480.
-
Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480.
-
Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in men with hormone-refractory prostate cancer.
-
Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in metastatic prostate cancer: a nested study within CALGB 9583.
-
Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy.
-
Prognostic value of various morphometric measurements of tumour extent in prostate needle core tissue.
-
Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer.
-
Proliferative index determination in prostatic carcinoma tissue: is there any additional prognostic value greater than that of Gleason score, ploidy and pathological stage?
-
Propensity Score-Matched Comparison of Partial to Whole-Gland Cryotherapy for Intermediate-Risk Prostate Cancer: An Analysis of the Cryo On-Line Data Registry Data.
-
Properties of prostatic cultures transformed by SV40.
-
ProstaScint (capromab pendetide) imaging using hybrid gamma camera-CT technology.
-
Prostate Cancer Detection Rate of Freehand versus 3-Dimensional Template Mapping Biopsy Using a Magnetic Resonance Imaging-Ultrasound Fusion Device in Biopsy Naïve Men.
-
Prostate Cancer Disseminated Tumor Cells are Rarely Detected in the Bone Marrow of Patients with Localized Disease Undergoing Radical Prostatectomy across Multiple Rare Cell Detection Platforms.
-
Prostate Cancer National Summit's Call to Action.
-
Prostate Cancer Patient Characteristics Associated With a Strong Preference to Preserve Sexual Function and Receipt of Active Surveillance.
-
Prostate Cancer and Prostatic Diseases. Report from Durham.
-
Prostate Cancer, Version 1.2016.
-
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.
-
Prostate Specific Antigen Density as a Predictor of Clinically Significant Prostate Cancer When the Prostate Specific Antigen is in the Diagnostic Gray Zone: Defining the Optimum Cutoff Point Stratified by Race and Body Mass Index.
-
Prostate Specific Antigen Nadir of 0.1 or Less Is a Predictor of Treatment Success in Men Undergoing Salvage Whole Prostate Gland Cryoablation.
-
Prostate and transitional cell carcinoma: radioimmunoassay of viral tumor-associated antigens.
-
Prostate apoptosis response protein 4 sensitizes human colon cancer cells to chemotherapeutic 5-FU through mediation of an NF kappaB and microRNA network.
-
Prostate biopsies from black men express higher levels of aggressive disease biomarkers than prostate biopsies from white men.
-
Prostate biopsy in selecting candidates for hemiablative focal therapy.
-
Prostate biopsy protocols: 3D visualization-based evaluation and clinical correlation.
-
Prostate biopsy quantitative histology as a staging and prognostic factor.
-
Prostate brachytherapy: a descriptive analysis from CaPSURE.
-
Prostate cancer 1997--practicing what we preach.
-
Prostate cancer and chip specimens: complete versus partial sampling.
-
Prostate cancer and the hypofractionation hypothesis.
-
Prostate cancer cell proliferation in vitro is modulated by antibodies against glucose-regulated protein 78 isolated from patient serum.
-
Prostate cancer early detection, version 1.2014. Featured updates to the NCCN Guidelines.
-
Prostate cancer early detection. Clinical practice guidelines in oncology.
-
Prostate cancer gene therapy.
-
Prostate cancer in African American men.
-
Prostate cancer in African Americans: relationship of patient and partner self-efficacy to quality of life.
-
Prostate cancer in North Carolina.
-
Prostate cancer in men age 50 years or younger: a review of the Department of Defense Center for Prostate Disease Research multicenter prostate cancer database.
-
Prostate cancer in men of African origin.
-
Prostate cancer in the Baby Boomer generation: results from CaPSURE.
-
Prostate cancer in the late 1990s: hormone refractory disease options.
-
Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer.
-
Prostate cancer laterality does not predict prostate-specific antigen recurrence after radical prostatectomy.
-
Prostate cancer originating in basal cells progresses to adenocarcinoma propagated by luminal-like cells.
-
Prostate cancer screening.
-
Prostate cancer screening. Why the controversy?
-
Prostate cancer surgical practice guidelines. Society of Surgical Oncology practice guidelines.
-
Prostate cancer susceptibility polymorphism rs2660753 is not associated with invasive ovarian cancer.
-
Prostate cancer treatment unblinded.
-
Prostate cancer with solitary parotid metastasis correctly diagnosed with immunohistochemical stains.
-
Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines.
-
Prostate cancer, version 1.2014.
-
Prostate cancer, version 2.2014.
-
Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4.
-
Prostate cancer-specific mortality after radical prostatectomy or external beam radiation therapy in men with 1 or more high-risk factors.
-
Prostate cancer.
-
Prostate cancer.
-
Prostate cancer: a significant risk factor for late-life suicide.
-
Prostate cancer: an evolving paradigm.
-
Prostate cancer: demographic and behavioral correlates of stage at diagnosis among blacks and whites in North Carolina.
-
Prostate cancer: diagnosis, treatment, and experience at one tertiary-care military medical center, 1989 and 1994.
-
Prostate cancer: ideal candidates for focal therapy.
-
Prostate cancer: making the switch from LHRH antagonist to LHRH agonist.
-
Prostate cancer: molecular and cellular mechanisms and their implications in therapy resistance and disease progression.
-
Prostate cancer: status of current treatments and emerging antisense-based therapies.
-
Prostate cancer: the new landscape.
-
Prostate carcinoma patients upstaged by imaging and treated with irradiation. An outcome-based analysis.
-
Prostate epithelial cell of origin determines cancer differentiation state in an organoid transformation assay.
-
Prostate intrafraction motion assessed by simultaneous kV fluoroscopy at MV delivery II: adaptive strategies.
-
Prostate intrafraction motion assessed by simultaneous kilovoltage fluoroscopy at megavoltage delivery I: clinical observations and pattern analysis.
-
Prostate intrafraction motion evaluation using kV fluoroscopy during treatment delivery: a feasibility and accuracy study.
-
Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: a search database study.
-
Prostate specific antigen density is not an independent predictor of response for prostate cancer treated by conformal radiotherapy.
-
Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy.
-
Prostate specific antigen kinetics at tumor recurrence after radical prostatectomy do not suggest a worse disease prognosis in black men.
-
Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer: the relationship between nadir level and disease-free survival.
-
Prostate specific antigen only progression of prostate cancer.
-
Prostate specific antigen progression rates after radical prostatectomy or radiation therapy for localized prostate cancer.
-
Prostate specific antigen recurrence after definitive therapy.
-
Prostate specific antigen: a decade of discovery--what we have learned and where we are going.
-
Prostate-Confined Radiation Decreased Pelvic Ganglia Neuronal Survival and Outgrowth.
-
Prostate-Specific Membrane Antigen-Targeted Radiohalogenated PET and Therapeutic Agents for Prostate Cancer.
-
Prostate-specific antigen (PSA) and PSA velocity for prostate cancer detection in men aged <50 years.
-
Prostate-specific antigen 1.5-4.0 ng/mL: a diagnostic challenge and danger zone.
-
Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer.
-
Prostate-specific antigen as a marker of disease activity in prostate cancer.
-
Prostate-specific antigen as a marker of disease activity in prostate cancer.
-
Prostate-specific antigen dynamics predict individual responses to intermittent androgen deprivation.
-
Prostate-specific antigen endpoints in hormone-refractory prostate cancer.
-
Prostate-specific antigen in black men.
-
Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database.
-
Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure.
-
Prostate-specific antigen screening among young men in the United States.
-
Prostate-specific antigen to predict outcome of external beam radiation for prostate cancer: Walter Reed Army Medical Center experience, 1988-1995.
-
Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men.
-
Prostate-specific antigen velocity based risk-adapted discontinuation of prostate cancer screening in elderly men.
-
Prostate-specific antigen velocity: new methods, same results, still no evidence of clinical utility.
-
Prostate-specific antigen versus prostate-specific antigen density as predictor of tumor volume, margin status, pathologic stage, and biochemical recurrence of prostate cancer.
-
Prostate-specific antigen-based risk-adapted discontinuation of prostate cancer screening in elderly African American and Caucasian American men.
-
Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality.
-
Prostate-specific antigen-detected prostate cancer (stage T1c): an analysis of whole-mount prostatectomy specimens.
-
Prostate-specific antigen-enhanced testing and risk stratification for chemoprevention trials.
-
Prostate-specific expression of p53(R172L) differentially regulates p21, Bax, and mdm2 to inhibit prostate cancer progression and prolong survival.
-
Prostatectomy vs brachytherapy for localized prostate cancer.
-
Prostatic abscess as a delayed complication following cryosurgery for primary prostate cancer.
-
Prostatic adenocarcinoma with atrophic features: a study of 202 consecutive completely embedded radical prostatectomy specimens.
-
Prostatic alpha-linolenic acid (ALA) is positively associated with aggressive prostate cancer: a relationship which may depend on genetic variation in ALA metabolism.
-
Prostatic carcinosarcoma 15 years after combined external beam radiation and brachytherapy for prostatic adenocarcinoma: a case report.
-
Prostatic disorders: MR imaging at 1.5 T.
-
Prostatic malignancy.
-
Prostatic mucinous adenocarcinoma. A Cowper gland carcinoma mimicker.
-
Prostatic sarcoma with rapid tumor progression after nerve sparing radical cystoprostatectomy.
-
Protective immunosurveillance and therapeutic antitumor activity of gammadelta T cells demonstrated in a mouse model of prostate cancer.
-
Protein C inhibitor (plasminogen activator inhibitor-3) expression in the CWR22 prostate cancer xenograft.
-
Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer.
-
Proteomics in prostate cancer.
-
Proton-beam therapy after radical prostatectomy: Continued DVH idolatry?
-
Pseudohyperplastic prostatic adenocarcinoma.
-
Psychological impact of diagnosis and risk reduction among cancer survivors.
-
Psychometric Evaluation of PROMIS Sexual Function and Satisfaction Measures in a Longitudinal Population-Based Cohort of Men With Localized Prostate Cancer.
-
Psychosocial aspects of active surveillance.
-
Psychosocial stress and prostate cancer: a theoretical model.
-
Psychosocial trajectories of men monitoring prostate-specific antigen levels following surgery for prostate cancer.
-
Pubic Bone Osteomyelitis and Pubosymphyseal Urinary Fistula: A Poorly Recognized Complication in Prostate Cancer Survivors.
-
Pubic Bone Resection Provides Objective Pain Control in the Prostate Cancer Survivor With Pubic Bone Osteomyelitis With an Associated Urinary Tract to Pubic Symphysis Fistula.
-
Pubic symphysis osteomyelitis in the prostate cancer survivor: clinical presentation, evaluation, and management.
-
Public survey and survival data do not support recommendations to discontinue prostate-specific antigen screening in men at age 75.
-
Pulmonary hemorrhage syndrome as a manifestation of disseminated intravascular coagulation: analysis of ten cases.
-
Putting Provenge in perspective.
-
Putting Provenge in perspective.
-
QOL and outcomes research in prostate cancer patients with low socioeconomic status.
-
Quality assurance for online adapted treatment plans: benchmarking and delivery monitoring simulation.
-
Quality of Life in Patients With Low-Risk Prostate Cancer Treated With Hypofractionated vs Conventional Radiotherapy: A Phase 3 Randomized Clinical Trial.
-
Quality of life after prostate cancer treatment.
-
Quality of life and trial adherence among participants in the prostate, lung, colorectal, and ovarian cancer screening trial.
-
Quality of life associated with treatment of castration-resistant prostate cancer: a review of the literature.
-
Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy.
-
Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480.
-
Quantification of prostate and seminal vesicle interfraction variation during IMRT.
-
Quantifying the dosimetric trade-offs when using intensity-modulated radiotherapy to treat concave targets containing normal tissues.
-
Quantitative comparison of automatic and manual IMRT optimization for prostate cancer: the benefits of DVH prediction.
-
Quantitative evaluation of cone-beam computed tomography in target volume definition for offline image-guided radiation therapy of prostate cancer.
-
Quantitative expression profile of PSGR in prostate cancer.
-
Quantitative expression profile of androgen-regulated genes in prostate cancer cells and identification of prostate-specific genes.
-
RNA Splicing of the BHC80 Gene Contributes to Neuroendocrine Prostate Cancer Progression.
-
RNASEL mutations in hereditary prostate cancer.
-
RRR-alpha-vitamin E succinate potentiates the antitumor effect of calcitriol in prostate cancer without overt side effects.
-
RTOG GU Radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer.
-
Race and prostate weight as independent predictors for biochemical recurrence after radical prostatectomy.
-
Race and risk of metastases and survival after radical prostatectomy: Results from the SEARCH database.
-
Race and the linkage between serum prostate-specific antigen and prostate cancer: a study of American veterans.
-
Race is associated with discontinuation of active surveillance of low-risk prostate cancer: results from the Duke Prostate Center.
-
Race/ethnicity and the intensity of medical monitoring under 'watchful waiting' for prostate cancer.
-
Race/ethnicity and the receipt of watchful waiting for the initial management of prostate cancer.
-
Racial Differences in the Association Between Preoperative Serum Cholesterol and Prostate Cancer Recurrence: Results from the SEARCH Database.
-
Racial differences in adipose tissue distribution and risk of aggressive prostate cancer among men undergoing radiotherapy.
-
Racial differences in patterns of treatment among men diagnosed with de novo advanced prostate cancer: A SEER-Medicare investigation.
-
Racial differences in prostate cancer risk remain among US servicemen with equal access to care.
-
Racial differences in prostate cancer screening by family history.
-
Racial differences in tumor volume and prostate specific antigen among radical prostatectomy patients.
-
Racial/ethnic disparities in de novo metastases sites and survival outcomes for patients with primary breast, colorectal, and prostate cancer.
-
Racial/ethnic disparities in the treatment of localized/regional prostate cancer.
-
Radiation Therapy Oncology Group. Research Plan 2002-2006. Genitourinary Cancer Committee.
-
Radiation and a metalloporphyrin radioprotectant in a mouse prostate tumor model.
-
Radiation dose to the neurovascular bundles or penile bulb does not predict erectile dysfunction after prostate brachytherapy.
-
Radiation therapy after radical prostatectomy for prostate cancer: evaluation of complications and influence of radiation timing on outcomes in a large, population-based cohort.
-
Radiation therapy for prostate cancer.
-
Radiation therapy versus delayed androgen deprivation for stage C carcinoma of the prostate.
-
Radical perineal prostatectomy for the treatment of localized prostate cancer in morbidly obese patients.
-
Radical perineal prostatectomy.
-
Radical perineal prostatectomy: a model for evaluating local response of prostate therapy.
-
Radical perineal prostatectomy: oncological outcome during a 20-year period.
-
Radical perineal vs. retropubic prostatectomy: a review of optimal application and technical considerations in the utilization of these exposures.
-
Radical prostatectomy and cryotherapy--some answers, more questions.
-
Radical prostatectomy and the effect of close surgical margins: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
-
Radical prostatectomy for clinical stage T1-2N0M0 prostatic adenocarcinoma: long-term results.
-
Radical prostatectomy in stage A prostatic adenocarcinoma.
-
Radical prostatectomy lowers plasma vascular endothelial growth factor levels in patients with prostate cancer.
-
Radical prostatectomy versus observation for localized prostate cancer.
-
Radical prostatectomy versus radiation therapy for clinically localized prostate carcinoma: the butcher and the baker selling their wares.
-
Radical prostatectomy versus radiation therapy: can pretreatment nomograms be used to select the appropriate prostate cancer treatment?
-
Radical prostatectomy.
-
Radical prostatectomy: anatomical predictors of success or failure.
-
Radical prostatectomy: the pros and cons of the perineal versus retropubic approach.
-
Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome.
-
Radical retropubic prostatectomy: the influence of accessory pudendal arteries on the recovery of sexual function.
-
Radical surgery versus radiation therapy in early prostatic carcinoma.
-
Radical surgery versus radiotherapy for adenocarcinoma of the prostate.
-
Radioactive sources embedded in suture are associated with improved postimplant dosimetry in men treated with prostate brachytherapy.
-
Radioisotope bone scanning characteristics of metastatic skeletal deposits of prostatic adenocarcinoma.
-
Radiotherapy before and after radical prostatectomy for high-risk and locally advanced prostate cancer.
-
Radiotherapy following radical prostatectomy.
-
Radiotherapy for locally recurrent prostate cancer.
-
Radiotherapy treatment plans with RapidArc for prostate cancer involving seminal vesicles and lymph nodes.
-
Radiotherapy versus surgery for localized prostatic cancer.
-
Radiotherapy: Secondary malignancies after prostate cancer treatment.
-
RalA regulates vascular endothelial growth factor-C (VEGF-C) synthesis in prostate cancer cells during androgen ablation.
-
Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer.
-
Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance).
-
Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer.
-
Randomized series of treatment with surgery versus radiation for prostate adenocarcinoma.
-
Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480.
-
Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.
-
Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer.
-
Rapid rise of serum prostate specific antigen levels after discontinuation of the herbal therapy PC-SPES in patients with advanced prostate carcinoma: report of four cases.
-
Rare Germline Pathogenic Mutations of DNA Repair Genes Are Most Strongly Associated with Grade Group 5 Prostate Cancer.
-
Rare germline mutations in African American men diagnosed with early-onset prostate cancer.
-
Rational basis for Trk inhibition therapy for prostate cancer.
-
Rationale for immunotoxin therapy of metastatic prostate carcinoma formatted as a multi-stage delivery system.
-
Rationale of technical requirements for NRG-BR001: The first NCI-sponsored trial of SBRT for the treatment of multiple metastases.
-
Re-calibration and external validation of an existing nomogram to predict aggressive recurrences after radical prostatectomy.
-
Re-induction of hormonal sensitivity in hormone-refractory prostate cancer--fact or fiction?
-
Re-purposing cryoablation: a combinatorial 'therapy' for the destruction of tissue.
-
Re: Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens.
-
Re: Association of Black Race with Prostate Cancer-specific and Other-cause Mortality Dess RT, Hartman HE, Mahal BA, et al JAMA Oncol 2019;5:975-83.
-
Re: Dosimetric consequences of increased seed strength for I-125 prostate implants. Radiother Oncol. 2003 Sep;68(3):295-7.
-
Re: Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer.
-
Re: Osteoporosis after orchiectomy for prostate cancer.
-
Re: Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy.
-
Re: Prevalence and Prognosis of Low-volume, Oligorecurrent, Hormone-sensitive Prostate Cancer Amenable to Lesion Ablative Therapy.
-
Re: Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy with Brachytherapy Boost and Disease Progression and Mortality in Patients with Gleason Score 9-10 Prostate Cancer.
-
Re: Saturation technique does not improve cancer detection as an initial prostate biopsy strategy. J. S. Jones, A. Patel, L. Schoenfield, J. C. Rabets, C. D. Zippe and C. Magi-Galluzzi. J Urol, 175: 485-488, 2006.
-
Re: The development of erectile dysfunction in men treated for prostate cancer.
-
Re: The number of cores positive for high grade prostatic intraepithelial neoplasia on initial biopsy is associated with prostate cancer on second biopsy: C. De Nunzio, A. Trucchi, R. Miano, A. Stoppacciaro, H. Fattahi, A. Cicione and A. Tubaro J Urol 2009; 181: 1069-1075.
-
Re: the economic burden of metastatic and prostate specific antigen progression in patients with prostate cancer: findings from a retrospective analysis of health plan data.
-
Reach out to ENhancE Wellness in Older Cancer Survivors (RENEW): design, methods and recruitment challenges of a home-based exercise and diet intervention to improve physical function among long-term survivors of breast, prostate, and colorectal cancer.
-
Real-Time Transferrin-Based PET Detects MYC-Positive Prostate Cancer.
-
Real-time quantitative RT-PCR assay of prostate-specific antigen and prostate-specific membrane antigen in peripheral blood for detection of prostate cancer micrometastasis.
-
Reassessing the diagnostic yield of saturation biopsy of the prostate.
-
Recent advances in the management of castration-resistant prostate cancer.
-
Recent advances in the treatment of prostate cancer.
-
Receptor tyrosine kinases as rational targets for prostate cancer treatment: platelet-derived growth factor receptor and imatinib mesylate.
-
Receptor-recognized αâ‚‚-macroglobulin binds to cell surface-associated GRP78 and activates mTORC1 and mTORC2 signaling in prostate cancer cells.
-
Recombinant adenovirus vector expressing wild-type p53 is a potent inhibitor of prostate cancer cell proliferation.
-
Recombinant human uteroglobin inhibits the in vitro invasiveness of human metastatic prostate tumor cells and the release of arachidonic acid stimulated by fibroblast-conditioned medium.
-
Recombinant oncolytic poliovirus, PVSRIPO, has potent cytotoxic and innate inflammatory effects, mediating therapy in human breast and prostate cancer xenograft models.
-
Recommended patient-reported core set of symptoms to measure in prostate cancer treatment trials.
-
Recruitment experience in the first phase of the African American Hereditary Prostate Cancer (AAHPC) study.
-
Rectourethral fistula after combination radiotherapy for prostate cancer.
-
Rectourethral fistulas in the cancer survivor.
-
Reduced Core Targeted (RCT) biopsy: Combining multiparametric magnetic resonance imaging - transrectal ultrasound fusion targeted biopsy with laterally-directed sextant biopsies - An alternative template for prostate fusion biopsy.
-
Reduced expression of hMSH2 and hMLH1 and risk of prostate cancer: a case-control study.
-
Reducing biochemical recurrence rates in EBRT-treated prostate cancer patients: the influence of dose and dose per fraction.
-
Reduction of human prostate tumor vascularity by the alpha1-adrenoceptor antagonist terazosin.
-
Regarding Mohan, Kuplian, and Willoughby, IJROBP 2000;46:575-580.
-
Relationship between body mass index and prostate cancer screening in the United States.
-
Relationship between obesity and race in predicting adverse pathologic variables in patients undergoing radical prostatectomy.
-
Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer.
-
Reliability and validity of PROMIS measures administered by telephone interview in a longitudinal localized prostate cancer study.
-
Reply by Authors.
-
Reply to A. Dalla Volta et al.
-
Reply to F. Valcamonico et al.
-
Reply: To PMID 25432832.
-
Report from Durham.
-
Report from Durham.
-
Report from Durham.
-
Report from Durham.
-
Report from Durham.
-
Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage.
-
Resident involvement and experience do not affect perioperative complications following robotic prostatectomy.
-
Residual disease after radical surgery or radiation therapy for prostate cancer. Clinical significance and therapeutic implications.
-
Resource Use in the Last Year of Life Among Patients Who Died With Versus of Prostate Cancer.
-
Response to docetaxel/carboplatin in patients with hormone-refractory prostate cancer not responding to taxane-based chemotherapy.
-
Results from the Quality Research in Radiation Oncology (QRRO) survey: Evaluation of dosimetric outcomes for low-dose-rate prostate brachytherapy.
-
Results of a phase II trial of transrectal ultrasound-guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (radiation therapy oncology group 98-05).
-
Results of radical prostatectomy in men with clinically localized prostate cancer.
-
Results of radical prostatectomy in men with locally advanced prostate cancer: multi-institutional pooled analysis.
-
Resveratrol worsens survival in SCID mice with prostate cancer xenografts in a cell-line specific manner, through paradoxical effects on oncogenic pathways.
-
Review: alcohol and other factors related to late prostate radiation injury.
-
Rhabdomyosarcoma in adult prostate.
-
Rising PSA Level in an Anxious Postprostatectomy Patient.
-
Rising PSA after local therapy failure: immediate vs deferred treatment.
-
Rising PSA in nonmetastatic prostate cancer.
-
Rising prostate-specific antigen after primary prostate cancer therapy.
-
Risk Stratification Among Men With Prostate Imaging Reporting and Data System version 2 Category 3 Transition Zone Lesions: Is Biopsy Always Necessary?
-
Risk factors for perineal seeding of prostate cancer after needle biopsy.
-
Risk of Prostate Cancer Associated With Familial and Hereditary Cancer Syndromes.
-
Risk of death from prostate cancer after radical prostatectomy or brachytherapy in men with low or intermediate risk disease.
-
Robot-assisted laparoscopic prostatectomy is not associated with early postoperative radiation therapy.
-
Robotic ultrasound and needle guidance for prostate cancer management: review of the contemporary literature.
-
Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017.
-
Role of multiparametric magnetic resonance imaging (MRI) in focal therapy for prostate cancer: a Delphi consensus project.
-
Role of oxidative stress in a rat model of radiation-induced erectile dysfunction.
-
Role of salvage lymph node dissection in prostate cancer.
-
Role of transrectal ultrasonography (TRUS) in focal therapy of prostate cancer: report from a Consensus Panel.
-
Role of vitamin D(3) as a sensitizer to cryoablation in a murine prostate cancer model: preliminary in vivo study.
-
Roles of Alternative RNA Splicing of the Bif-1 Gene by SRRM4 During the Development of Treatment-induced Neuroendocrine Prostate Cancer.
-
Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy.
-
Rural-urban differences in health behaviors and outcomes among older, overweight, long-term cancer survivors in the RENEW randomized control trial.
-
SPARED Collaboration: Patient Selection for Partial Gland Ablation in Men with Localized Prostate Cancer.
-
SPOP Promotes Nanog Destruction to Suppress Stem Cell Traits and Prostate Cancer Progression.
-
SV40-transformed hamster prostatic tissue: a model of human prostatic malignancy.
-
Salvage Prostate Cryoablation for the Management of Local Recurrence After Primary Cryotherapy: A Retrospective Analysis of Functional and Intermediate-Term Oncological Outcomes Associated With a Second Therapeutic Freeze.
-
Salvage Radiation Therapy Dose Response for Biochemical Failure of Prostate Cancer After Prostatectomy-A Multi-Institutional Observational Study.
-
Salvage Radiotherapy for Recurrent Prostate Cancer: Can the Prognostic Grade Group System Inform Treatment Timing?
-
Salvage high-intensity focused ultrasound (HIFU) for locally recurrent prostate cancer after failed radiation therapy: Multi-institutional analysis of 418 patients.
-
Salvage radiation in men after prostate-specific antigen failure and the risk of death.
-
Salvage radiotherapy for rising or persistent PSA after radical prostatectomy.
-
Sample size calculation for simulation-based multiple-testing procedures.
-
Sample size calculations for evaluating a diagnostic test when the gold standard is missing at random.
-
Sample size determination for comparing several survival curves with unequal allocations.
-
Sampling the spatial patterns of cancer: optimized biopsy procedures for estimating prostate cancer volume and Gleason Score.
-
Scanning and transmission electron microscopy of human prostatic acinar cells.
-
Scanning electron microscopy of hyperplastic and neoplastic human prostate.
-
Scatter factor-hepatocyte growth factor elevation in the serum of patients with prostate cancer.
-
Screening for familial and hereditary prostate cancer.
-
Screening for prostate cancer in African Americans.
-
Screening for prostate cancer in high risk populations.
-
Screening for prostate cancer in military populations.
-
Screening for prostate cancer utilizing the prostate-specific antigen (PSA).
-
Second-line chemotherapy for advanced hormone-refractory prostate cancer.
-
Secondary screening tests for prostate cancer: is more information better? Which test is best?
-
Secreted Hsp90 is a novel regulator of the epithelial to mesenchymal transition (EMT) in prostate cancer.
-
Seduced by dose?
-
Seduced by technology?
-
Selective aromatase inhibition for patients with androgen-independent prostate carcinoma.
-
Selective upregulated expression of the alpha2-macroglobulin signaling receptor in highly metastatic 1-LN prostate carcinoma cells.
-
Self-Assembling Peptide Gels for 3D Prostate Cancer Spheroid Culture.
-
Self-Management in Long-Term Prostate Cancer Survivors: A Randomized, Controlled Trial.
-
Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial.
-
Serial carcinoembryonic antigen assays in patients with metastatic carcinoma of prostate being treated with chemotherapy.
-
Serine and Methionine Metabolism: Vulnerabilities in Lethal Prostate Cancer.
-
Serum Lipids prior to Starting Androgen Deprivation Therapy and Risk of Castration Resistant Prostate Cancer and Metastasis: Results from the SEARCH Database.
-
Serum Prostate-Specific Antigen (PSA) Concentration, PSA Mass, and Obesity: A Mathematical Analysis.
-
Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy.
-
Serum androgens: associations with prostate cancer risk and hair patterning.
-
Serum androgens: associations with prostate cancer risk and hair patterning.
-
Serum antibodies to huntingtin interacting protein-1: a new blood test for prostate cancer.
-
Serum cholesterol and risk of high-grade prostate cancer: results from the REDUCE study.
-
Serum cholesterol and risk of lower urinary tract symptoms progression: Results from the Reduction by Dutasteride of Prostate Cancer Events study.
-
Serum cholesterol levels and tumor growth in a PTEN-null transgenic mouse model of prostate cancer.
-
Serum lipid profile and risk of prostate cancer recurrence: Results from the SEARCH database.
-
Serum prostate-specific antigen (PSA) concentration is positively associated with rate of disease reclassification on subsequent active surveillance prostate biopsy in men with low PSA density.
-
Sexual bother and function after radical prostatectomy: predictors of sexual bother recovery in men despite persistent post-operative sexual dysfunction.
-
Sexually transmitted infections and prostate cancer among men in the U.S. military.
-
Shared heritability and functional enrichment across six solid cancers.
-
Short communication: CT-MRI image fusion for 3D conformal prostate radiotherapy: use in patients with altered pelvic anatomy.
-
Short-course androgen ablation combined with external-beam radiation therapy and low-dose-rate permanent brachytherapy in early-stage prostate cancer: a matched subset analysis.
-
Short-term cancer control after primary cryosurgical ablation for clinically localized prostate cancer using third-generation cryotechnology.
-
Should function and bother be measured and reported separately for prostate cancer quality-of-life domains?
-
Significance of familial history of prostate cancer to traditional prognostic variables, genetic biomarkers, and recurrence after radical prostatectomy.
-
Significance of tertiary Gleason pattern 5 in Gleason score 7 radical prostatectomy specimens.
-
Significant discrepancies between diagnostic and pathologic Gleason sums in prostate cancer: the predictive role of age and prostate-specific antigen.
-
Similarities between static and rotational intensity-modulated plans.
-
Simulation of electromagnetically induced hyperthermia: a finite element gridding method.
-
Simulation optimization of PSA-threshold based prostate cancer screening policies.
-
Single institution's dosimetry and IGRT analysis of prostate SBRT.
-
Single-Cell RNA-seq Reveals a Subpopulation of Prostate Cancer Cells with Enhanced Cell-Cycle-Related Transcription and Attenuated Androgen Response.
-
Single-nucleotide polymorphisms of stemness genes predicted to regulate RNA splicing, microRNA and oncogenic signaling are associated with prostate cancer survival.
-
Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis.
-
Six Questions to Ask Before We Shorten Radiation Treatments for Intact Prostate Cancer.
-
Small-Molecule-Mediated Degradation of the Androgen Receptor through Hydrophobic Tagging.
-
Smoking and risk of low- and high-grade prostate cancer: results from the REDUCE study.
-
Smoking is a predictor of adverse pathological features at radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital database.
-
Snail promotes resistance to enzalutamide through regulation of androgen receptor activity in prostate cancer.
-
Socioeconomic status, race, and long-term outcomes after radical prostatectomy in an equal access health system: Results from the SEARCH database.
-
Special concerns for survivors of prostate cancer.
-
Spontaneous metastasis of cells of the human prostate carcinoma cell line PC-3 in athymic nude mice.
-
Spontaneously acquired anti-factor VIII antibodies: report of a patient with adenocarcinoma of the prostate.
-
Squamous cell carcinoma of the prostate: 2 cases of a rare malignancy and review of the literature.
-
Stability of self-reported family history of prostate cancer among African American men.
-
Staging evaluation for patients with adenocarcinoma of the prostate. American College of Radiology. ACR Appropriateness Criteria.
-
Staging lymphadenectomy should not be an antecedent to treatment in localized prostatic carcinoma.
-
Staging pelvic lymphadenectomy for carcinoma of the prostate risk versus benefit.
-
Standardization of definitions in focal therapy of prostate cancer: report from a Delphi consensus project.
-
Statin Use, Serum Lipids, and Prostate Inflammation in Men with a Negative Prostate Biopsy: Results from the REDUCE Trial.
-
Statin use and longitudinal changes in prostate volume; results from the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial.
-
Statin use is associated with decreased prostate cancer recurrence in men treated with brachytherapy.
-
Statins are Associated With Increased Biochemical Recurrence After Radical Prostatectomy in Diabetic Men but no Association was Seen in Men also Taking Metformin: Results From the SEARCH Database.
-
Statistical considerations for the design and analysis of Phase III clinical trials in prostate cancer.
-
Statistical modeling using preoperative prognostic variables in predicting extracapsular extension and progression after radical prostatectomy for prostate cancer.
-
Stereotactic Body Radiation Therapy for Oligometastatic Prostate Cancer: The Hunt for the Silver Bullet.
-
Steroid 5-alpha-reductase type 2 (SRD5A2) V89L and A49T polymorphisms and sporadic prostate cancer risk: a meta-analysis.
-
Strategies for automatic online treatment plan reoptimization using clinical treatment planning system: a planning parameters study.
-
Stratification of pathologic features in radical prostatectomy specimens that are predictive of elevated initial postoperative serum prostate-specific antigen levels.
-
Stress urinary incontinence in the prostate cancer survivor.
-
Successful fertilization and pregnancy outcome in in-vitro fertilization using cryopreserved/thawed spermatozoa from patients with malignant diseases.
-
Successful outcome of artificial urinary sphincters in men with post-prostatectomy urinary incontinence despite adverse implantation features.
-
Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial.
-
Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy.
-
Supplement use among men with prostate cancer.
-
Suppression of CHK1 by ETS Family Members Promotes DNA Damage Response Bypass and Tumorigenesis.
-
Suppression of RelB-mediated manganese superoxide dismutase expression reveals a primary mechanism for radiosensitization effect of 1alpha,25-dihydroxyvitamin D(3) in prostate cancer cells.
-
Suramin keratosis: a unique skin eruption in a patient receiving suramin for metastatic prostate cancer.
-
Surface-enhanced Raman scattering detection and tracking of nanoprobes: enhanced uptake and nuclear targeting in single cells.
-
Surgical control of clinically localized prostate carcinoma is equivalent in African-American and white males.
-
Surgical management of complex rectourethral fistulas in irradiated and nonirradiated patients.
-
Surrogate end point for prostate cancer specific mortality in patients with nonmetastatic hormone refractory prostate cancer.
-
Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy.
-
Surveillance after prostate focal therapy.
-
Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555).
-
Symptom and function profiles of men with localized prostate cancer.
-
Symptoms, weight loss, and physical function in a lifestyle intervention study of older cancer survivors.
-
Syndecan-1 expression in prostate cancer and its value as biomarker for disease progression.
-
Syntaxin 6-mediated exosome secretion regulates enzalutamide resistance in prostate cancer.
-
Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers.
-
Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer.
-
Systematic biopsies: do they add prognostic information in men with clinically localized prostate cancer treated with radiation therapy alone?
-
Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma.
-
Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors.
-
Systemic strategies for prostate cancer.
-
Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer.
-
Systemic therapy for prostate cancer.
-
TET2 binds the androgen receptor and loss is associated with prostate cancer.
-
TMPRSS2-ERG fusion is frequently observed in Gleason pattern 3 prostate cancer in a Canadian cohort.
-
TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation.
-
Targeted Anterior Gland Focal Therapy-a Novel Treatment Option for a Better Defined Disease.
-
Targeted Biopsy to Detect Gleason Score Upgrading during Active Surveillance for Men with Low versus Intermediate Risk Prostate Cancer.
-
Targeted prostate biopsies: the complexity behind a simple concept.
-
Targeted prostate biopsy using statistical image analysis.
-
Targeting PDGF receptors in cancer--rationales and proof of concept clinical trials.
-
Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancer.
-
Targeting the androgen receptor--theory and practice.
-
Telephone monitoring of distress in patients aged 65 years or older with advanced stage cancer: a cancer and leukemia group B study.
-
Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer.
-
Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era.
-
Tenascin expression in prostatic hyperplasia, intraepithelial neoplasia, and carcinoma.
-
Testosterone in prostate cancer: the Bethesda consensus.
-
The 1999 patterns of care study of radiotherapy in localized prostate carcinoma: a comprehensive survey of prostate brachytherapy in the United States.
-
The Association between Phosphodiesterase Type 5 Inhibitors and Prostate Cancer: Results from the REDUCE Study.
-
The CLN3 gene is a novel molecular target for cancer drug discovery.
-
The COMPARE Registry: design and baseline patterns of care for men with biochemical failure after definitive treatment of localized prostate cancer.
-
The Calculus of Serum PSA.
-
The Contemporary Role of Multiparametric Magnetic Resonance Imaging in Active Surveillance for Prostate Cancer.
-
The DNA methylation landscape of advanced prostate cancer.
-
The Diet Quality Index-Revised: a tool to promote and evaluate dietary change among older cancer survivors enrolled in a home-based intervention trial.
-
The Escherichia coli subtilase cytotoxin A subunit specifically cleaves cell-surface GRP78 protein and abolishes COOH-terminal-dependent signaling.
-
The Impact of Late Luteinizing Hormone-Releasing Hormone Agonist Dosing on Testosterone Suppression in Patients with Prostate Cancer: An Analysis of United States Clinical Data.
-
The Importance of Tumor Length in Needle Biopsies of the Prostate.
-
The Molecular Taxonomy of Primary Prostate Cancer.
-
The National Cancer Data Base report on prostate cancer.
-
The Physician Recommendation Coding System (PhyReCS): A Reliable and Valid Method to Quantify the Strength of Physician Recommendations During Clinical Encounters.
-
The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer.
-
The Role of CD44 in Glucose Metabolism in Prostatic Small Cell Neuroendocrine Carcinoma.
-
The STAMPEDE trial and celecoxib: how to adapt?
-
The Stability of Physician-Specific Episode Costs for Urologic Cancer Surgery: Implications for Urologists Under the Merit-Based Incentive Program.
-
The UroLume stent revisited: the Duke experience.
-
The activity of camptothecin analogues is enhanced in histocultures of human tumors and human tumor xenografts by modulation of extracellular pH.
-
The alpha 1C-adrenoceptor in human prostate: cloning, functional expression, and localization to specific prostatic cell types.
-
The antioxidant, MnTE-2-PyP, prevents side-effects incurred by prostate cancer irradiation.
-
The association between race and prostate cancer risk on initial biopsy in an equal access, multiethnic cohort.
-
The association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy.
-
The association between sexual function and prostate cancer risk in US veterans.
-
The association of exercise with both erectile and sexual function in black and white men.
-
The association of oncogenic human papillomaviruses with urologic malignancy. The controversies and clinical implications.
-
The changing face of prostate cancer.
-
The clinical spectrum of prostate cancer.
-
The comprehensive role of E-cadherin in maintaining prostatic epithelial integrity during oncogenic transformation and tumor progression.
-
The contemporary value of pretreatment prostatic acid phosphatase to predict pathological stage and recurrence in radical prostatectomy cases.
-
The correlation of serial prostate specific antigen measurements with clinical outcome after external beam radiation therapy of patients for prostate carcinoma.
-
The critical use of population-based medical databases for prostate cancer research.
-
The development of a web- and a print-based decision aid for prostate cancer screening.
-
The development of erectile dysfunction in men treated for prostate cancer.
-
The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival.
-
The dynamics of death in prostate cancer.
-
The dynamics of prostate specific antigen during watchful waiting of prostate carcinoma: a study of 94 Japanese men.
-
The dynamics of prostate specific antigen in hormone refractory prostate carcinoma: an analysis of cancer and leukemia group B study 9181 of megestrol acetate.
-
The dynamics of prostate-specific antigen after definitive radiation therapy for prostate cancer.
-
The effect of carbohydrate restriction on prostate cancer tumor growth in a castrate mouse xenograft model.
-
The effect of noise-cancelling headphones or music on pain perception and anxiety in men undergoing transrectal prostate biopsy.
-
The effect of pelvic radiation therapy on serum levels of prostate specific antigen.
-
The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance).
-
The effect of race on the discriminatory accuracy of models to predict biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases.
-
The effects of cancer and racial disparities in health-related quality of life among older Americans: a case-control, population-based study.
-
The effects of castration on adrenal testosterone secretion in men with prostatic carcinoma.
-
The effects of varying dietary carbohydrate and fat content on survival in a murine LNCaP prostate cancer xenograft model.
-
The efficacy of postprostatectomy radiotherapy in patients with an isolated elevation of serum prostate-specific antigen.
-
The ethics of hypofractionation for prostate cancer.
-
The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation.
-
The evolving role of chemotherapy in androgen-independent (hormone-refractory) prostate cancer.
-
The experiences of unpartnered men with prostate cancer: a qualitative analysis.
-
The homeodomain protein HOXB13 regulates the cellular response to androgens.
-
The impact of PSA on prostate cancer management. Can we abandon routine staging pelvic lymphadenectomy?
-
The impact of current staging procedures in assessing disease extent of prostatic adenocarcinoma.
-
The impact of docetaxel, estramustine, and low dose hydrocortisone on the quality of life of men with hormone refractory prostate cancer and their partners: a feasibility study.
-
The impact of pathology review on treatment recommendations for patients with adenocarcinoma of the prostate.
-
The impact of prior radical prostatectomy in men with metastatic castration recurrent prostate cancer: a pooled analysis of 9 Cancer and Leukemia Group B Trials.
-
The influence of statin medications on prostate-specific antigen levels.
-
The management of clinically localized prostate cancer. A summary of the Consensus Statement of the National Institutes of Health.
-
The metabolic co-regulator PGC1α suppresses prostate cancer metastasis.
-
The multidisciplinary approach to adenocarcinoma of the prostate at Moore Regional Hospital.
-
The natural course of prostatic carcinoma in relation to initial cytological grade.
-
The needs for men undergoing active surveillance (AS) for prostate cancer: results of a focus group study.
-
The number of high-risk factors and the risk of prostate cancer-specific mortality after brachytherapy: implications for treatment selection.
-
The optimisation of wedge filters in radiotherapy of the prostate.
-
The optimization and inherent limitations of 3D conformal radiotherapy treatment plans of the prostate.
-
The preoperative use of erythropoietin stimulating proteins prior to radical prostatectomy is not associated with increased cardiovascular or thromboembolic morbidity or mortality.
-
The prognostic role of lymphadenectomy in adenocarcinoma of the prostate.
-
The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480.
-
The ratio of prostate chips with cancer: a new measure of tumor extent and its relationship to grade and prognosis.
-
The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer.
-
The relative importance of anatomic and PSA factors to outcomes after radical prostatectomy for prostate cancer.
-
The relevance of stage A malignancy in prostatic cancer.
-
The role of androgen deprivation therapy combined with prostate brachytherapy.
-
The role of epithelial plasticity in prostate cancer dissemination and treatment resistance.
-
The role of imaging studies and molecular markers for selecting candidates for radical prostatectomy.
-
The role of magnetic resonance imaging (MRI) in focal therapy for prostate cancer: recommendations from a consensus panel.
-
The role of radical prostatectomy in patients with pretreatment prostate-specific antigen > or = 40 ng/mL.
-
The role of radical surgery in the management of radiation recurrent and large volume prostate cancer.
-
The role of seminal vesicle motion in target margin assessment for online image-guided radiotherapy for prostate cancer.
-
The role of surgery in stage B-2 malignancy.
-
The role of surrogate markers in the management of men with metastatic castration-resistant prostate cancer.
-
The role of the p53 tumor suppressor gene in prostate cancer: a possible biomarker?
-
The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer.
-
The significance of syndecan-1 expression in patients treated with radical prostatectomy. Commentary.
-
The state of prostate MRI in 2013.
-
The synthetic phosphagen cyclocreatine phosphate inhibits the growth of a broad spectrum of solid tumors.
-
The therapeutic and preventive effect of RRR-alpha-vitamin E succinate on prostate cancer via induction of insulin-like growth factor binding protein-3.
-
The type III transforming growth factor-beta receptor as a novel tumor suppressor gene in prostate cancer.
-
The use of multiparametric MRI in diagnosis and active surveillance of prostate cancer.
-
The value of pathologic factors in predicting cancer-specific survival among patients treated with radical cystectomy for transitional cell carcinoma of the bladder and prostate.
-
The watchful waiting management option for older men with prostate cancer: state of the science.
-
Therapeutic properties of aerobic training after a cancer diagnosis: more than a one-trick pony?
-
Three IMRT advanced planning tools: A multi-institutional side-by-side comparison.
-
Three-dimensional computer-simulated prostate models: lateral prostate biopsies increase the detection rate of prostate cancer.
-
Three-dimensional localization and targeting of prostate cancer foci with imaging and histopathologic correlation: establishing a multidisciplinary team for quality improvement.
-
Through COVID-Colored Glasses: New Perspectives on Same Data.
-
Time for a neoadjuvant chemotherapy strategy in prostate cancer?
-
Timing and patterns of recurrences and deaths from prostate cancer following adjuvant pelvic radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate.
-
Timing of Prostate-specific Antigen Nadir After Radical Prostatectomy and Risk of Biochemical Recurrence.
-
Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study.
-
Tissue factor is the receptor for plasminogen type 1 on 1-LN human prostate cancer cells.
-
Tocopherol-associated protein suppresses prostate cancer cell growth by inhibition of the phosphoinositide 3-kinase pathway.
-
Tolerance doses for late adverse events after hypofractionated radiotherapy for prostate cancer on trial NRG Oncology/RTOG 0415.
-
Tortuous and aberrant external iliac artery precluding radical retropubic prostatectomy for prostate cancer.
-
Toxicity and quality of life report of a phase II study of stereotactic body radiotherapy (SBRT) for low and intermediate risk prostate cancer.
-
Tradeoffs of integrating real-time tracking into IGRT for prostate cancer treatment.
-
Traditional approaches to androgen deprivation therapy.
-
Trainees do not negatively impact the institutional learning curve for robotic prostatectomy as characterized by operative time, estimated blood loss, and positive surgical margin rate.
-
Transatlantic Consensus Group on active surveillance and focal therapy for prostate cancer.
-
Transcription factor TFII-I causes transcriptional upregulation of GRP78 synthesis in prostate cancer cells.
-
Transcriptional regulation of core autophagy and lysosomal genes by the androgen receptor promotes prostate cancer progression.
-
Transitional cell carcinoma in a prostatic remnant 10 years after radical cystectomy.
-
Transrectal gene therapy of the prostate in the canine model.
-
Treating the biochemical recurrence of prostate cancer after definitive primary therapy.
-
Treatment considerations for persons with metastatic prostate cancer: survival versus out-of-pocket costs.
-
Treatment of PSA only recurrence of prostate cancer after prior local therapy.
-
Treatment of locally confined prostatic cancer. Radiotherapy versus surgery: limits of curability.
-
Treatment of metastatic endocrine-unresponsive carcinoma of the prostate gland with multiagent chemotherapy: indicators of response to therapy.
-
Treatment options for patients with prostate cancer who develop metastatic disease after hormonal therapy.
-
Treatment options, selection, and satisfaction among African American and white men with prostate carcinoma in North Carolina.
-
Treatment patterns for prostate cancer: comparison of Medicare claims data to medical record review.
-
Treatment planning for clinically localized prostate cancer. American College of Radiology. ACR Appropriateness Criteria.
-
Treatment planning for prostate brachytherapy using region of interest adjoint functions and a greedy heuristic.
-
Treatment-related neuroendocrine prostate cancer resulting in Cushing's syndrome.
-
Trefoil factor 1 acts to suppress senescence induced by oncogene activation during the cellular transformation process.
-
TrueNTH sexual recovery study protocol: a multi-institutional collaborative approach to developing and testing a web-based intervention for couples coping with the side-effects of prostate cancer treatment in a randomized controlled trial.
-
Tumor Repression of VCaP Xenografts by a Pyrrole-Imidazole Polyamide.
-
Tumor blood flow measured by PET dynamic imaging of first-pass 18F-FDG uptake: a comparison with 15O-labeled water-measured blood flow.
-
Tumor length in prostate cancer.
-
Tumor percent involvement predicts prostate specific antigen recurrence after radical prostatectomy only in men with smaller prostate.
-
Tumor volume changes on 1.5 tesla endorectal MRI during neoadjuvant androgen suppression therapy for higher-risk prostate cancer and recurrence in men treated using radiation therapy results of the phase II CALGB 9682 study.
-
Tumor volume in prostate cancer and serum prostate-specific antigen. Analysis from a kinetic viewpoint.
-
Tumor volume, tumor percentage involvement, or prostate volume: which is predictive of prostate-specific antigen recurrence?
-
Tunable cytotoxic aptamer-drug conjugates for the treatment of prostate cancer.
-
Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer.
-
Twenty-five year evolution of medical hormonal therapy for prostate cancer.
-
Two novel PRKCI polymorphisms and prostate cancer risk in an Eastern Chinese Han population.
-
Type IV collagenase (matrix metalloproteinase-2 and -9) in prostate cancer.
-
U19/Eaf2 knockout causes lung adenocarcinoma, B-cell lymphoma, hepatocellular carcinoma and prostatic intraepithelial neoplasia.
-
UDP-glucuronosyltransferases and biochemical recurrence in prostate cancer progression.
-
Uncertainty and perception of danger among patients undergoing treatment for prostate cancer.
-
Uncertainty intervention for watchful waiting in prostate cancer.
-
Understanding the pathological features of focality, grade and tumour volume of early-stage prostate cancer as a foundation for parenchyma-sparing prostate cancer therapies: active surveillance and focal targeted therapy.
-
Unmasking of Urinary-pubic Symphysis Fistula After Implantation of Artificial Urinary Sphincter in Prostate Cancer Survivors-User Beware.
-
Update in the management of patients with hormone-refractory prostate cancer.
-
Update on brachytherapy in localized prostate cancer: the importance of dosimetry.
-
Update on cryotherapy for prostate cancer in 2006.
-
Update on outcomes research databases in prostate cancer 2006.
-
Update on transrectal ultrasound-guided needle biopsy of the prostate.
-
Updated insights into genetic contribution to prostate cancer predisposition: focus on HOXB13.
-
Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer.
-
Updates in advanced prostate cancer 2018.
-
Upregulation of VEGF-C by androgen depletion: the involvement of IGF-IR-FOXO pathway.
-
Upregulation of mTORC2 activation by the selective agonist of EPAC, 8-CPT-2Me-cAMP, in prostate cancer cells: assembly of a multiprotein signaling complex.
-
Ureteral reimplantation for inadvertent ureteral injury during radical perineal prostatectomy.
-
Urethroplasty for radiotherapy induced bulbomembranous strictures: a multi-institutional experience.
-
Urinary continence and quality of life in the first year after radical perineal prostatectomy.
-
Urinary incontinence following external-beam radiotherapy for clinically localized prostate cancer.
-
Urinary outcomes are significantly affected by nerve sparing quality during radical prostatectomy.
-
Use of 1,25α dihydroxyvitamin D3 as a cryosensitizing agent in a murine prostate cancer model.
-
Use of 111in-capromab pendetide immunoscintigraphy to image localized prostate cancer foci within the prostate gland.
-
Use of Routine Home Health Care and Deviations From an Uncomplicated Recovery Pathway After Radical Prostatectomy.
-
Use of local (111)in-capromab pendetide scan results to predict outcome after salvage radiotherapy for prostate cancer.
-
Use of prostate-specific antigen in black men: age-adjusted reference ranges for maximal cancer detection.
-
Use of prostate-specific antigen in the follow-up of patients with localized prostate cancer: results of a nationwide survey of urologists.
-
Use of serum creatinine to predict pathologic stage and recurrence among radical prostatectomy patients.
-
Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literature.
-
Using the percentage of biopsy cores positive for cancer, pretreatment PSA, and highest biopsy Gleason sum to predict pathologic stage after radical prostatectomy: the Center for Prostate Disease Research nomograms.
-
Usual and unusual histologic patterns of high Gleason score 8 to 10 adenocarcinoma of the prostate in needle biopsy tissue.
-
Uteroglobin: a potential novel tumor suppressor and molecular therapeutic for prostate cancer.
-
Utility of LHRH antagonists for advanced prostate cancer.
-
Utility of a 3-dimensional transrectal ultrasound-guided prostate biopsy system for prostate cancer detection.
-
Utility of capromab pendetide (ProstaScint) imaging in the management of prostate cancer.
-
Utilization and impact of surgical technique on the performance of pelvic lymph node dissection at radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital database.
-
Utilization of (111)In-Capromab pendetide SPECT-CT for detecting seminal vesicle invasion with recurrent prostate cancer after primary in situ therapy.
-
Utilization of a Genomic Classifier for Prediction of Metastasis Following Salvage Radiation Therapy after Radical Prostatectomy.
-
Utilization of multiparametric prostate magnetic resonance imaging in clinical practice and focal therapy: report from a Delphi consensus project.
-
Utilization of surgical procedures and racial disparity in the treatment of urinary incontinence after prostatectomy.
-
Utilization trends at a multidisciplinary prostate cancer clinic: initial 5-year experience from the Duke Prostate Center.
-
Utilizing knowledge from prior plans in the evaluation of quality assurance.
-
Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes.
-
Vaccination with mRNAs encoding tumor-associated antigens and granulocyte-macrophage colony-stimulating factor efficiently primes CTL responses, but is insufficient to overcome tolerance to a model tumor/self antigen.
-
Validation of the 2015 prostate cancer grade groups for predicting long-term oncologic outcomes in a shared equal-access health system.
-
Validity of the National Death Index to ascertain the date and cause of death in men having undergone prostatectomy for prostate cancer.
-
Value of Tracking Biopsy in Men Undergoing Active Surveillance of Prostate Cancer.
-
Value of cyclophosphamide or melphalan as combined chemotherapy in hormonally unresponsive prostatic carcinoma.
-
Variability of the Positive Predictive Value of PI-RADS for Prostate MRI across 26 Centers: Experience of the Society of Abdominal Radiology Prostate Cancer Disease-focused Panel.
-
Variables in predicting survival based on treating "PSA-only" relapse.
-
Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes.
-
Variation in the definition of clinical target volumes for pelvic nodal conformal radiation therapy for prostate cancer.
-
Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study.
-
Vegetable Consumption and Progression of Prostate Cancer.
-
Vincristine, bleomycin, methotrexate, 5-fluorouracil, and prednisone in metastatic, hormonally unresponsive prostatic adenocarcinoma.
-
Viral neoplastic transformation of hamster prostate tissue in vitro.
-
Virus-induced genitourinary malignancy. Macromolecular identity.
-
Vitamin D and prostate cancer survival in veterans.
-
Vitamin D and prostate cancer: a prediagnostic study with stored sera.
-
Vitamin D receptor polymorphisms and prostate cancer.
-
Vitamin D(3) cryosensitization increases prostate cancer susceptibility to cryoablation via mitochondrial-mediated apoptosis and necrosis.
-
Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT).
-
Vitamin E succinate inhibits human prostate cancer cell growth via modulating cell cycle regulatory machinery.
-
Volumetric-modulated arc therapy: effective and efficient end-to-end patient-specific quality assurance.
-
Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition.
-
Watchful waiting and factors predictive of secondary treatment of localized prostate cancer.
-
Watching, waiting and uncertainty in prostate cancer.
-
We need better randomized comparison trials of prostate cancer.
-
Weekly docetaxel in elderly patients with prostate cancer: efficacy and toxicity in patients at least 70 years of age compared with patients younger than 70 years.
-
What Is Oligometastatic Prostate Cancer?
-
What Should We Tell Patients About Physical Activity After a Prostate Cancer Diagnosis?
-
What the U.S. Preventive Services Task Force missed in its prostate cancer screening recommendation.
-
What to order from the prostate cancer treatment menu?
-
When should we pull the trigger for post-radical prostatectomy radiotherapy?
-
When to diagnose and how to treat prostate cancer in the "not too fit" elderly.
-
Will the future of health care lead to the end of the robotic golden years?
-
Will the global economic downturn affect prostate cancer care? Pelvic lymphadenectomy as an example.
-
Words of wisdom. Re: Tracking the clonal origin of lethal prostate cancer.
-
X-linked inhibitor of apoptosis deficiency in the TRAMP mouse prostate cancer model.
-
X-linked inhibitor of apoptosis protein inhibition induces apoptosis and enhances chemotherapy sensitivity in human prostate cancer cells.
-
XIAP as target for therapeutic apoptosis in prostate cancer.
-
Yes or no to local therapy for oligometastatic prostate cancer?
-
Young patients with prostate cancer have an outcome justifying their treatment with external beam radiation.
-
Zinc alpha-2-glycoprotein is expressed by malignant prostatic epithelium and may serve as a potential serum marker for prostate cancer.
-
[Variation of mortality risk among cancer patients and individualized therapy].
-
c-Jun Contributes to Transcriptional Control of GNA12 Expression in Prostate Cancer Cells.
-
hZip2 and hZip3 zinc transporters are down regulated in human prostate adenocarcinomatous glands.
-
iDQC anisotropy map imaging for tumor tissue characterization in vivo.
-
p53 Immunostaining guided laser capture microdissection (p53-LCM) defines the presence of p53 gene mutations in focal regions of primary prostate cancer positive for p53 protein.
-
p53 and bcl-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy.
-
p53 gene alterations in human prostate carcinoma.
-
p53 immunohistochemical and genetic alterations are associated at high incidence with post-irradiated locally persistent prostate carcinoma.
-
p53 nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy.
-
p53 protein expression status and recurrence in men treated with radiation and androgen suppression therapy for higher-risk prostate cancer: a prospective phase II Cancer and Leukemia Group B Study (CALGB 9682).
-
p53 regulates the expression of the tumor suppressor gene maspin.
-
p53-dependent induction of heat shock protein 27 (HSP27) expression.
-
p63 expression profile in normal and malignant prostate epithelial cells.
-
Keywords of People
-
-
Berchuck, Andrew,
James M. Ingram Distinguished Professor of Gynecologic Oncology,
Obstetrics and Gynecology, Gynecologic Oncology
-
Chitneni, Satish K.,
Associate Professor in Radiology,
Radiology
-
Grambow, Steven C.,
Assistant Professor of Biostatistics and Bioinformatics,
Biostatistics & Bioinformatics
-
Inman, Brant Allen,
Cary N. Robertson, MD, Associate Professor,
Surgery, Urology
-
Koontz, Bridget Fey,
Associate Professor of Radiation Oncology,
Radiation Oncology
-
McDonnell, Donald Patrick,
Glaxo-Wellcome Distinguished Professor of Molecular Cancer Biology, in the School of Medicine,
Duke Innovation & Entrepreneurship
-
Moorman, Patricia Gripka,
Professor in Family Medicine and Community Health,
Duke Cancer Institute
-
O'Daniel, Jennifer Colleen,
Assistant Professor of Radiation Oncology,
Radiation Oncology
-
Preminger, Glenn Michael,
James F. Glenn, M.D. Distinguished Professor of Urology,
Surgery
-
Reed, Shelby Derene,
Professor in Population Health Sciences,
Duke Science & Society
-
Routh, Jonathan Charles,
Paul H. Sherman, M.D. Distinguished Associate Professor of Surgery,
Pediatrics
-
Shinohara, Mari L.,
Associate Professor of Immunology,
Immunology
-
Yoo, Sua,
Associate Professor of Radiation Oncology,
Radiation Oncology